



## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>6</sup> :</b> <b>C12N 15/12, C07K 14/705, C12N 5/10,</b> <b>C12Q 1/68, C12N 15/62, C07K 16/28</b>	<b>A2</b>	<b>(11) International Publication Number:</b> <b>WO 99/09166</b>  <b>(43) International Publication Date:</b> 25 February 1999 (25.02.99)
<b>(21) International Application Number:</b> PCT/US98/17058 <b>(22) International Filing Date:</b> 18 August 1998 (18.08.98)  <b>(30) Priority Data:</b> 60/056,110                      20 August 1997 (20.08.97)      US 09/112,096                      9 July 1998 (09.07.98)              US  <b>(71) Applicant (for all designated States except US):</b> DENDREON CORPORATION [US/US]; 291 North Bernardo Avenue, Mountain View, CA 94043 (US).  <b>(72) Inventors; and</b> <b>(75) Inventors/Applicants (for US only):</b> LAUS, Reiner [DE/US]; 3813 Porto Rosa Way, San Carlos, CA 94070 (US). SHAPERO, Michael, H. [US/US]; 2449 Carson Street, Redwood City, CA 94061 (US). TSAVALER, Larisa [US/US]; 43 Walnut Avenue, Atherton, CA 94027 (US).  <b>(74) Agents:</b> JUDGE, Linda, R. et al.; Dehlinger & Associates, P.O. Box 60850, Palo Alto, CA 94306-0850 (US).		<b>(81) Designated States:</b> AU, CA, JP, NZ, US, European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).  <b>Published</b> <i>Without international search report and to be republished upon receipt of that report.</i> <i>With an indication in relation to deposited biological material furnished under Rule 13bis separately from the description.</i>
<b>(54) Title:</b> PROSTATE TUMOR POLYNUCLEOTIDE AND ANTIGEN COMPOSITIONS		
<b>(57) Abstract</b>		
<p>The present invention is directed to novel polynucleotides and the polypeptides encoded by them, each of which are specific to human prostate tumor cells. The present invention further provides chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, and antibodies which bind to the polypeptides of the present invention. Also provided herein are methods for producing the polypeptides of the present invention, as are detection assays that detect the presence of tumor cells in tissue or bodily fluid samples and methods for identifying novel compositions which modulate the activity of prostate tumor antigens and the use of such compositions in diagnosis and treatment of disease.</p>		

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

---

## PROSTATE TUMOR POLYNUCLEOTIDE AND ANTIGEN COMPOSITIONS

---

### Field of the Invention

- 5           The invention relates to novel coding sequences and peptides derived from prostate tumors and to methods for detecting the presence of such tumor cells.

### Background of the Invention

- Prostate carcinoma is a form of cancer that afflicts approximately 250,000 men in the United States each year, making it one of the most frequent cancers in Americans. It is also the second leading cause of cancer-related deaths in males in this country. While five-year survival rates for prostate carcinoma have generally improved over the past several decades, treatment for the advanced, metastatic form of the disease has not improved significantly.

- Early detection and treatment of prostate cancer therefore remains one of the most effective measures to prevent further spread of and mortality from the disease. While a number of protein antigens have been discovered that are characteristic of malignant tumors, prostate tumors have not been particularly rich sources of target antigens that might be used for detection and/or immunotherapy of the disease, such as by passive immunotherapy.

- It would therefore be useful to provide one or more disease-specific molecules or antigens that can be used in the early detection of prostate cancer. The present invention provides novel nucleotide sequences and corresponding expressed antigens that are useful in both the diagnosis and treatment of prostate carcinoma.

### Summary of the Invention

- 25           According to one aspect, the present invention is concerned with isolated nucleic acid molecules, which can be any form of RNA or DNA molecule that is useful, particularly in the area of diagnostic detection methods. The nucleic acid molecules described herein were identified on the basis of their unique presence in prostate tumor tissue samples. The molecules therefore have utility in detecting the presence, in a tissue or bodily fluid sample, of prostate tumor cells.

- 30           In one embodiment, the polynucleotides of the invention contain a region having sequence identity to a sequence selected from the group consisting of SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, and SEQ ID NO:8, and SEQ ID NO:14, or is complementary to such encoding nucleic acid sequences.

In another embodiment, the polynucleotides of the invention will hybridize under high stringency conditions to a sequence selected from the group consisting of SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, and SEQ ID NO:8, and SEQ ID NO:14, or the complement thereof.

5 Generally, according to a preferred aspect, the polynucleotide will be less than about 10 kilobases in length. In still a further aspect, the invention includes the recited polynucleotides. The invention also includes fragments of the polynucleotides of the present invention. In still another related aspect, the invention encompasses RNA molecules that are formed by translation of the foregoing nucleic acid sequences.

10 The isolated nucleic acid sequence may comprise the cDNA inserts of three pCR2.1 plasmid vectors (Invitrogen, San Diego, CA). The three clones which together make up the full-length SP 1-4 (SEQ ID NO:14) sequence are designated pCR2.1/SP 1-4 (5' RACE, SEQ ID NO:27), pCR2.1/SP 1-4 (3' RACE, SEQ ID NO:28) and pCT2.1/SP 1-4 (SEQ ID NO:29). The approximate lengths of the plasmid inserts are 1700, 3850 and 350 base pairs, respectively. The vectors deposited on August  
15 6, 1998 as ATCC 98828, 98829 and 98827 include the nucleotide sequences encoding SEQ ID NO:15.

In another embodiment, the invention provides a vector comprising DNA encoding a prostate tumor antigen. A host cell comprising such a vector is also provided. By way of example, the host cells may be CHO cells, *E. coli*, insect cells or yeast. A process for producing prostate tumor antigens is further provided and comprises culturing host cells under conditions suitable for expression of a  
20 prostate tumor antigen and recovering the prostate tumor antigen from the cell culture.

Also useful and forming a part of the present invention are isolated nucleic acid molecules comprising DNA encoding prostate tumor antigens. In one aspect, the isolated nucleic acid comprises DNA encoding a prostate tumor antigen having an amino acid sequence selected from the group consisting of SEQ ID NOs:9-11 and 15, or is complementary to such encoding nucleic acid sequences,  
25 and remains stably bound to it under at least moderate, and optionally, under high stringency conditions. Such peptides have utility in diagnostic assays, as well as in antigen compositions, such as peptide vaccines for use in eliciting humoral or cellular immune responses.

The invention further provides chimeric molecules comprising a prostate tumor antigen or extracellular domain thereof fused to a heterologous polypeptide or amino acid sequence. An example  
30 of such a chimeric molecule comprises a prostate tumor antigen fused to heterologous polypeptide which enhances the immunogenic properties of the antigen.

The invention also includes fragments of a prostate tumor antigen.

A further aspect of the invention is one or more antibodies which specifically bind to a prostate tumor antigen or an extracellular domain thereof. Optionally, the antibody is a monoclonal  
35 antibody. In still another aspect, the invention includes an antibody specific for a prostate tumor

antigen. The antibody has diagnostic and therapeutic applications, particularly in treating prostate-related malignant disorders. Treatment methods include, but are not limited to, those which employ antisense or coding sequence polynucleotides for modulating the expression of prostate tumor antigen, as are treatment methods which employ antibodies specific for a prostate tumor antigen.

5 Diagnostic methods for detecting a prostate tumor antigen in specific tissue samples, and for detecting levels of expression of a prostate tumor antigen in tissues, also form part of the invention.

Furthermore, the polynucleotides recited above have particular utility in various nucleic acid-based detection assays. Exemplary assays include *in situ* hybridization assays and PCR-based assays.

The invention also provides methods for diagnosing a prostate tumor-related condition in an individual. The presence of a prostate tumor antigen in a tissue from a first individual is measured and compared to a tissue from a second, unaffected individual. When a prostate tumor antigen is detected in said first individual and not in said second individual, the first individual is at risk for a prostate tumor related condition.

These and other objects and features of the invention will become more fully apparent when the following detailed description of the invention is read in conjunction with the accompanying drawings.

#### Brief Description of the Figures

FIG. 1 shows the sequence of a prostate-tumor derived polynucleotide of the invention, identified herein as SEQ ID NO:1;

FIG. 2 shows the sequence of a prostate-tumor derived polynucleotide of the invention, identified herein as SEQ ID NO:2;

FIG. 3 shows the sequence of a prostate-tumor derived polynucleotide of the invention, identified herein as SEQ ID NO:3;

25 FIG. 4 shows the sequence of a prostate-tumor derived polynucleotide of the invention, identified herein as SEQ ID NO:4;

FIG. 5 shows the sequence of a prostate-tumor derived polynucleotide of the invention, identified herein as SEQ ID NO:5;

FIG. 6 shows the sequence of a prostate-tumor derived polynucleotide of the invention, identified herein as SEQ ID NO:6;

FIG. 7 shows the sequence of a prostate-tumor derived polynucleotide of the invention, identified herein as SEQ ID NO:7;

FIG. 8 shows the sequence of a prostate-tumor derived polynucleotide of the invention, identified herein as SEQ ID NO:8;

FIGS. 9A-9C show the sequences of three peptides derived from SEQ ID NO:5 as SEQ ID NO:9 (9A), SEQ ID NO:10 (9B) and SEQ ID NO:11 (9C).

FIG. 10 shows the sequence of a prostate-tumor derived polynucleotide of the invention, identified herein as SEQ ID NO:14; and

5 FIG. 11 shows the sequence of the polypeptide derived from SEQ ID NO:14, and identified as SEQ ID NO:15. The predicted 5' and 3' untranslated region of SEQ ID NO:14 is depicted in lower case, the open reading frame from positions 43 to 3227 depicted in upper case, and the original partial cDNA fragment (SEQ ID NO:29) shown as underlined.

## 10 Detailed Description of the Invention

The present invention relates to novel nucleotide sequences that are unique to prostate tumors, as evidenced by preferential expression of such sequences in prostate tumor tissue samples. These sequences, including sequence variants and extended sequences thereof, have utility in diagnostic assays of body fluids or biopsied tissue to detect the presence of tumor cells. The proteins and  
15 peptides expressed by such DNA molecules are also encompassed by the present invention and may be used in diagnostic assays, as well as in developing pharmacologic strategies for disease intervention including immunotherapy, *e.g.* the use of antibodies that are specifically targeted to tumor cells.

### I. Definitions

20 The term "polypeptide" as used herein refers to a compound made up of a single chain of amino acid residues linked by peptide bonds. The term "protein" as used herein may be synonymous with the term "polypeptide" or may refer, in addition, to a complex of two or more polypeptides.

Amino acid residues are referred to herein by their standard single letter notations: A, alanine; C, cysteine; D, aspartic acid; E, glutamic acid; F, phenylalanine; G, glycine; H, histidine; I,  
25 Isoleucine; K, lysine; L, leucine; M, methionine; N, asparagine; P, proline; Q, glutamine; R, arginine; S, serine; T, threonine; V, valine; W, tryptophan; Y, tyrosine.

The term "prostate tumor antigen" as used herein, encompasses native sequence prostate tumor antigens and polypeptide variants thereof. The prostate tumor antigen may be isolated from a variety of sources, such as from human tissue types or from another source, or prepared by recombinant or  
30 synthetic methods.

A "native sequence prostate tumor antigen" comprises a polypeptide having the same amino acid sequence as a prostate tumor antigen derived from nature. Such a native sequence prostate tumor antigen can be isolated from nature or can be produced by recombinant or synthetic means. The term "native sequence prostate tumor antigen" specifically encompasses naturally-occurring truncated or  
35 secreted forms of a prostate tumor antigen (*e.g.*, soluble forms containing for instance, an extracellular

domain sequence), naturally-occurring variant forms (*e.g.*, alternatively-spliced forms) and naturally-occurring allelic variants of a prostate tumor antigen.

5 "Percent (%) amino acid sequence identity" with respect to the amino acid sequences identified herein is defined as the percentage of amino acid residues in a candidate sequence that are identical with the amino acid residues in the native sequence, after aligning the sequences and introducing gaps, if necessary, to achieve the maximum percent sequence identity, and not considering any conservative substitutions as part of the sequence identity.

10 The term "polypeptide sequence variant" as used herein, refers to an active prostate tumor antigen having at least about 80% amino acid sequence identity with the prostate tumor antigen having the deduced amino acid sequences shown in Figures 9A-C and 11 (SEQ ID NOs:9-11 and 15, respectively) for a full-length native sequence prostate tumor antigen. Such prostate tumor antigen variants include, for instance, polypeptides wherein one or more amino acid residues are added, or deleted, at the N-or C-terminus of the sequence depicted in any one of Figures 9A-C and 11 (SEQ ID NOs:9-11 and 15, respectively).

15 The term "fragment," when referring to a prostate tumor antigen, means a polypeptide which has an amino acid sequence which is the same as part of, but not all of, the amino acid sequence of the prostate tumor antigen which either retains essentially the same biological function or activity as the prostate tumor antigen, or retains at least one of the functions or activities of prostate tumor antigen; for example, a fragment which retains the ability to bind to a receptor, or a fragment which  
20 retains immunological activity of the prostate tumor antigen. The fragment preferably includes at least about 100-200 contiguous amino acid residues of the prostate tumor antigen, more preferably at least about 20-100 contiguous amino acid residues, even more preferably at least about 10-20 contiguous amino acid residues, and most preferably at least about 9-10 contiguous amino acid residues of the prostate tumor antigen.

25 "Isolated", when used to describe the various polypeptides disclosed herein, means polypeptide that has been identified has also been separated and/or recovered from a component of its natural environment.

30 "Biologically active" or "biological activity" for the purposes herein refers to form(s) of prostate tumor antigen which retain the biologic and/or immunologic activities of the native or naturally-occurring prostate tumor antigen.

The term, "nucleic acid" as used herein refers to either DNA or RNA, or molecules which contain both deoxy-and ribonucleotides. The nucleic acids include genomic mRNA, DNA, cDNA, genomic DNA and oligonucleotides including sense and anti-sense nucleic acids. The term "nucleic acid" also includes fragments of the polynucleotides of the present invention, preferably at least about  
35 300-600 nucleotides in length, more preferably about 150-300 nucleotides in length, even more

preferably about 30-150 nucleotides in length, and most preferably about 27-30 nucleotides in length. Such nucleic acids may also contain modifications in the ribose-phosphate backbone to increase stability and half life of such molecules in physiological environments.

5 The nucleic acid may be double stranded, single stranded, or contain portions of both double stranded or single stranded sequence. The depiction of a single strand also defines the sequence of the other strand and thus also includes the complement of the sequence.

The term "polynucleotide" as used herein refers to a polymeric molecule having a backbone that supports bases capable of hydrogen bonding to typical polynucleotides, where the polymer backbone presents the bases in a manner to permit such hydrogen bonding in a sequence specific  
10 fashion between the polymeric molecule and a typical polynucleotide (*e.g.*, single-stranded DNA). Such bases are typically inosine, adenosine, guanosine, cytosine, uracil and thymidine. Polymeric molecules include double and single stranded ribonucleic acids (RNA) and deoxyribonucleic acids (DNA), and may include polymers having backbone modifications such as methylphosphonate linkages.

15 The term, "recombinant nucleic acid" as used herein refers to nucleic acid, originally formed *in vitro*, in general, by the manipulation of nucleic acid by endonucleases, in a form not normally found in nature.

Nucleic acid subunits are referred to herein by their standard base designations; T, thymine; A, adenosine; C, cytosine; G, guanine, U, uracil; variable positions are referred to by standard  
20 IUPAC abbreviations: W, A or T/U; R, A or G; S, C or G; K: G or T/U (37 CFR. §1.822).

"Percent (%) nucleic acid sequence identity" with respect to the prostate tumor antigen sequence identified herein is defined as the percentage of nucleotides in a candidate sequence that are identical with the nucleotides in the disclosed prostate tumor antigen sequence, after aligning the sequences and introducing gaps, if necessary, to achieve the maximum percent sequence identity.  
25 Alignment for purposes of determining percent nucleic acid sequence identity can be achieved in various ways that are within the skill in the art, for instance, using publicly available computer software such as ALIGN or Megalign (DNASTAR) software. Those skilled in the art can determine appropriate parameters for measuring alignment, including any algorithms needed to achieve maximal alignment over the length of the sequences being compared.

30 The term "vector" refers to a nucleotide sequence that can assimilate new nucleic acids, and propagate those new sequences in an appropriate host. Vectors include, but are not limited to recombinant plasmids and viruses. The vector (*e.g.*, plasmid or recombinant virus) comprising the nucleic acid of the invention can be in a carrier, for example, a plasmid complexed to a protein, a plasmid complexed with lipid-based nucleic acid transduction systems, or other non-viral carrier  
35 systems.



The term "control sequences" refers to DNA sequences necessary for the expression of an operably linked coding sequence in a particular host organism. The control sequences that are suitable for prokaryotes, for example, include a promoter, optionally an operator sequence, and a ribosome binding site. Eukaryotic cells are known to utilize promoters, polyadenylation signals, and enhancers.

5 The terms "polymerase chain reaction" and "PCR" refer to a process of amplifying one or more specific nucleic acid sequences, wherein (i) oligonucleotide primers which determine the ends of the sequences to be amplified are annealed to single-stranded nucleic acids in a test sample, (ii) a nucleic acid polymerase extends the 3' ends of the annealed primers to create a nucleic acid strand complementary in sequence to the nucleic acid to which the primers were annealed, (iii) the resulting  
10 double-stranded nucleic acid is denatured to yield two single-stranded nucleic acids, and (iv) the processes of primer annealing, primer extension, and product denaturation are repeated enough times to generate easily identified and measured amounts of the sequences defined by the primers. The sequential annealing, extension and denaturation steps are controlled by varying the temperature of the reaction container, normally in a repeating cyclical manner. Annealing and extension are typically  
15 carried out between 40-80°C, whereas denaturation requires temperatures between about 80 and 100°C. A "thermal cycler", such as Perkin Elmer Model 9600, is typically used to regulate the reactions.

The term "antibody" is used in the broadest sense and specifically covers single anti-prostate tumor antigen monoclonal antibodies (including agonist, antagonist, and neutralizing antibodies) and  
20 anti-prostate tumor antigen antibody compositions with polyepitopic specificity.

The term "monoclonal antibody" as used herein refers to an antibody obtained from a population of substantially homogeneous antibodies, *i.e.*, the individual antibodies comprising the population are identical except for possible naturally-occurring mutations that may be present in minor amounts.

25

## II. Identification of Prostate Tumor-Specific DNA Molecules

Prostate cancer-specific genes can be isolated by a various techniques known to those of skill in the art that allow for detection of differences in gene expression between two or more sources of nucleic acid, *e.g.* differential expression in response to temporal development, disease and/or  
30 mitogenic stimulus.

An "isolated" prostate tumor antigen-encoding nucleic acid is a nucleic acid molecule that is identified and separated from at least one contaminant with which it is ordinarily associated. An isolated prostate tumor antigen-encoding nucleic acid is other than in the form or setting in which it is found in nature and is therefore distinguished from such prostate tumor antigen-encoding nucleic  
35 acids as they exist in natural cells.

Using differential display or various subtractive hybridization strategies, mRNA derived from related cell types can be compared to provide qualitative and quantitative differences in specific mRNA species.

Differential display (DD) uses two different types of primers to convert different fractions of the mRNA pool constituency into double-stranded cDNA fragments. These fragments are separated electrophoretically to provide an expression profile "bar code." The first primer is generically referred to as the "anchored " primer. Most anchored primers use a group of 10-12 dTs to achieve annealing with the poly(A+) tail of the mRNAs. First strand cDNA synthesis occurs off the anchored primer, thereby anchoring to the 3' end of the transcript. Anchored primers employ either one or two non-dt bases to achieve annealing of the anchored primer to a subset of mRNAs within the mRNA pool. Single-base anchored primers generate three different fractions, corresponding to the presence of either a C, G or T immediately upstream of the poly(A+) region. Assuming 10,000-15,000 different species of mRNA present, each single-base anchored primer is expected to generate approximately 3,000-5,000 different first-strand cDNAs. There are twelve different two-base pair combinations possible immediately upstream of the poly(A+) region, with each representing a considerably smaller subset of the mRNA pool than single-base permutations. Each two-base anchored primer theoretically selects approximately 1/12 (8%) of the mRNA pool constituency, or approximately 800-1,200 different first-strand cDNAs. Anchored primers employing two non-dt bases to 'cull' the mRNA pool provide a more manageable number of cDNA fragments.

After first strand synthesis is complete, aliquots of the reactions are subjected to exponential (bi-directional) polymerase chain reaction (PCR) amplification using the original anchored primer in combination with a second, upstream or "arbitrary" primer. Arbitrary primers contain sequences that are designed to anneal at sites upstream of the anchored primer, converting the first-strand cDNA into one or more truncated cDNA fragments. The RNA samples to be compared serve as templates for first-strand cDNA synthesis in reverse transcription reactions using a set of 12 different oligo(dT) anchored 3' primers. The cDNAs produced in the RT reactions are then used in duplicate DD-PCR reactions using the same anchored 3' primers used in the RT reactions, in pairwise combinations with four different arbitrary 5' primers. Each RNA sample is amplified by 48 primer pair combinations. The duplicate DD-PCR samples are loaded on adjacent lanes of a high resolution denaturing gel, with samples from different RNAs amplified with the same anchored and arbitrary primer pairs, grouped together in consecutive lanes. Gels are subjected to autoradiography, and bands that appear in the prostate tumor-derived samples, but not in control samples (such as in normal prostate tissue or HeLa cell samples) are selected for further processing. Section IV provides details of the experimental procedures used in experiments carried out in support of the present invention.

As described in Example 1, when RNA from prostate tumor derived tissue was compared to RNA from normal prostate tissue or HeLa cell samples, 54 unique DD products were identified. The corresponding bands were excised from the gels, reamplified by PCR, gel purified and 5' ends were subjected to DNA sequencing by cycle sequencing.

5 Subtractive hybridization, followed by one or more rounds of PCR amplification of the sequences obtained following subtraction, is useful to isolate nucleic acids that are preferentially expressed, *e.g.* in disease state, but not in normal, healthy tissue or in one tissue type and not in another.

As described in Examples 3A-B, a prostate tumor specific partial cDNA sequence was  
10 identified using a subtractive hybridization strategy and PCR amplification, with the corresponding full length sequence identified by rapid amplification of cDNA ends [RACE, Frohman, *et al.*, *Proc. Nat. Acad. Sci.* **85**:8998-9002 (1988)], using a single gene-specific oligonucleotide primer.

The sequences were compared to published databanks, as discussed in Example 2, and eight novel mRNAs/CDNAs presented herein as SEQ ID NOs:1-4, and 6-8 were obtained by the differential  
15 display method with an additional sequence designated SP 1-4 (SEQ ID NO:14), obtained by subtractive hybridization. One of the sequences obtained by the differential display method, SEQ ID NO:5, was further found to have some degree of homology to thioredoxin reductase, according to methods detailed in Example 2.

## 20 A. Identification of Prostate Tumor-Specific DNA Sequence Variants and Peptides

The present invention encompasses, in addition to DNA molecules having the specific sequences recited herein, sequence variants, extended sequences and peptides derived from such sequences. This section describes how these various molecules are identified in accordance with the present invention.

25

### 1. DNA Sequence Variants

a. Sequence Identity and Specific Hybridization. A "variant" polynucleotide sequence encodes a "variant" amino acid sequence which is altered by one or more amino acids from the reference polypeptide sequence.

30

Sequence variants include polynucleotide sequences that have at least about 80% nucleic acid sequence identity, preferably at least about 85% nucleic acid sequence identity, more preferably at least about 90% nucleic acid sequence identity and even more preferably at least about 95-98% nucleic acid sequence identity with the nucleic acid sequence of any one of SEQ ID NOs:1-8 and 14, respectively.

Sequence identity in the context of a nucleic acid which encodes a prostate tumor antigen means identical nucleic acids at corresponding positions in the two sequences which are being compared. Sequence comparison are carried out using standard techniques known in the art, as detailed below in Section IIB.

5 A functional measure of sequence identity that may alternatively be used to assess similarity of sequences is the ability of a particular nucleotide molecule to hybridize with a second nucleotide under defined conditions. "Hybridization" includes any process by which a strand of a nucleic acid joins with a complementary strand through base-pairing. Thus, strictly speaking, the term refers to the ability of the complement of the test sequence to bind to the test sequence, or vice-versa.

10 The nucleic acid similarity may be determined through hybridization studies. Thus, for example, nucleic acids which hybridize under high stringency to the nucleic acid sequences shown in Figures 1-8 and 14, or the complement thereof, are considered a prostate tumor antigen gene. High stringency conditions are known in the art; an example of such conditions includes hybridization at about 65°C in about 5xSSPE and washing conditions of about 65°C in about 0.1x SSPE. See  
15 Maniatis, *et al.*, MOLECULAR CLONING: A LABORATORY MANUAL, 2d Edition (1989), and Ausubel, F.M., *et al.*, Eds., CURRENT PROTOCOLS IN MOLECULAR BIOLOGY, John Wiley & Sons, Inc., Copyright (c)1987, 1988, 1989, 1990 by Current Protocols, both of which are hereby incorporated by reference.

Hybridization conditions are based on the melting temperature ( $T_m$ ) of the nucleic acid  
20 binding complex or probe and are typically classified by degree of "stringency" of the conditions under which hybridization is measured. (Ausubel, *et al.*, 1990) For example, "maximum stringency" typically occurs at about  $T_m - 5^\circ\text{C}$  (5% below the  $T_m$  of the probe); "high stringency" at about 5-10° below the  $T_m$ ; "intermediate stringency" at about 10-20° below the  $T_m$  of the probe; and "low stringency" at about 20-25° below the  $T_m$ . Functionally, maximum stringency conditions may be  
25 used to identify sequences having strict identity or near-strict identity with the hybridization probe; while high stringency conditions are used to identify sequences having about 80% or more sequence identity with the probe.

## 2. Degeneracy of Genetic Code

30 Sequence variants also include nucleic acid molecules that encode the same peptide as is encoded by the tumor specific nucleic acid molecules described herein. Thus, where the coding frame of the various identified nucleic acid molecules is known, for example by homology to known genes or by extension of the sequence, as described in Parts B or C below, it is appreciated that as a result of the degeneracy of the genetic code, a number of coding sequences can be produced. For example,  
35 the triplet CGT encodes the amino acid arginine. Arginine is alternatively encoded by CGA, CGC,

CGG, AGA, and AGG. Therefore it is appreciated that such substitutions in the coding region fall within the sequence variants that are covered by the present invention. Any and all of these sequence variants can be utilized in the same ways as are described herein for the identified parent sequences SEQ ID NOs: 1-8.

5 It is further appreciated that such sequence variants may or may not hybridize to the parent sequence under conditions of high stringency. This would be possible, for example, when the sequence variant includes a different codon for each of the amino acids encoded by the parent nucleotide. Such variants are, nonetheless, specifically contemplated and encompassed by the present invention. In accordance with the present invention, also encompassed are sequences that at least 80%  
10 identical to such degeneracy-derived sequence variants.

Although nucleotide sequence variants are preferably capable of hybridizing to the nucleotide sequences recited herein under conditions of moderately high or high stringency, there are, in some situations, advantages to using variants based on the degeneracy of the code, as described above. For example, codons may be selected to increase the rate at which expression of the peptide occurs in a  
15 particular procaryotic or eukaryotic organism, in accordance with the optimum codon usage dictated by the particular host organism. Alternatively, it may be desirable to produce RNA having longer half lives than the mRNA produced by the recited sequences.

### 3. Extended Polynucleotide Sequences

20 Polynucleotide sequences recited herein may be extended using various methods known in the art to detect upstream sequences such as promoters and regulatory elements. For example, "restriction site" polymerase chain reaction is a direct method which uses universal primers to retrieve unknown sequences adjacent to a known sequence. First, a genomic DNA is amplified in the presence of a primer directed to a linker sequence and a primer specific to the known region. The amplified  
25 sequences are subjected to a second round of PCR with the same linker primer and another specific primer internal to the first one. Products of each round of PCR are transcribed with an appropriate RNA polymerase and sequenced using reverse transcriptase.

Likewise, a method known as "inverse PCR" can be used to amplify or extend sequences using divergent primers based on a known region. The primers may be designed using standard  
30 primer analysis software, for example GeneWorks (Oxford Biomolecular Systems, CA) to be at least 15 nt in length, with a GC content of 50% or more and to anneal to the target sequence at temperatures about 68-72°. The method requires the use of several restriction enzymes to generate a suitable fragment in the known region of a gene. The fragment is then circularized by ligation and is used as a PCR template. Alternatively, adjacent and full length sequences, and particularly,

intron/exon junctions, may be identified using a kit such as "PROMOTER-FINDER" (Clontech Labs, Palo Alto, CA). This kit uses PCR, nested primers and specific libraries to walk in genomic DNA.

Preferred libraries for screening for full-length cDNAs are ones that have been size-selected to include larger cDNAs. Random primed libraries are preferred since they contain more sequences  
5 which include the 5' and upstream regions of genes. Genomic libraries are useful for extension into the 5' nontranslated regulatory region. Preferably, such libraries will be generated from the tumor cells of interest, such as the prostate tumor cells exemplified herein.

Analysis of the size and sequence of full length sequences identified in accordance with the present invention may be carried out by standard methods known in the art, such as automated  
10 sequencing methods, gel size analysis and capillary electrophoresis.

Where the full length sequence is identified, it will be appreciated that additional regions of the full length sequence may be used to make hybridization probes and/or tumor detection reagents in accordance with the present invention. Specifically, knowledge of a partial or full-length sequence makes possible searches of widely available databases, in order to determine whether the subject  
15 sequence may have homologies in other species or tissues, particularly tumor tissues. Examples of homologies based on the current sequences are presented in Example 2, herein.

The full length sequence can also be used to construct a recombinant nucleic inserted into a vector and used to express the encoded polypeptide, as discussed in Part D, below.

It is understood that once a recombinant nucleic acid is made and reintroduced into a host cell  
20 or organism, it will replicate non-recombinantly, using the cellular machinery of the host cell, and such nucleic acids, once produced recombinantly, although subsequently replicated non-recombinantly, are still considered recombinant for the purposes of the invention.

#### 4. Polypeptide Variants

25 In one embodiment of the invention, the native sequence prostate tumor antigen is a mature or full-length native sequence prostate tumor antigen comprising amino acids 1 to 1095 of Figure 11 (SEQ ID NO:15). In another embodiment of the invention, the native sequence prostate tumor antigen is an extracellular domain of the full-length prostate tumor antigen. Optionally, the prostate tumor antigen is obtained or obtainable by expressing the polypeptide encoded by the cDNA insert of the  
30 vectors pCR2.1/SP 1-4 (5' RACE, SEQ ID NO:27), pCR2.1/SP 1-4 (3' RACE, SEQ ID NO:28) and pCT2.1/SP 1-4 (SEQ ID NO:29) deposited on August 6, 1998 as ATCC 98828, 98829 and 98827.

Ordinarily, a prostate tumor antigen variant will have at least about 80% amino acid sequence identity, preferably at least about 85% amino acid sequence identity, more preferably at least about 90% amino acid sequence identity and even more preferably at least about 95-98% amino acid

sequence identity with the amino acid sequence depicted in any one of Figures 9A-C and 11 (SEQ ID NOs:9-11 and 15, respectively).

Sequence similarity in the context of a prostate tumor antigen means sequence similarity or identity, with identity being preferred. Identical in this context means identical amino acids at corresponding positions in the two sequences which are being compared. Similarity in this context includes amino acids which are identical and those which are similar (functionally equivalent). This similarity or identity will be determined using standard techniques known in the art, for example, the "Best Fit" sequence program described by Devereux, *et al.*, *Nucl. Acid Res.* 12:387-395 (1984), the BLASTP or BLASTX program [Altshul, *et al.*, *Methods in Enzymology* 266:460-480 (1990), *Nucl. Acids Res.* 25:3389-3402 (1997)], preferably using the default settings. The alignment may include the introduction of gaps in the sequences to be aligned. In addition, for sequences which contain either more or fewer amino acids than the relevant native protein, it is understood that the percentage of similarity will be determined based on the number of similar or identical amino acids in relation to the total number of amino acids. Alignment for purposes of determining percent amino acid sequence identity can be achieved in various ways that are within the skill in the art, for instance, using publicly available computer software such as LALIGN or Megalign (DNASTAR) software with default parameters. The LALIGN program is found in the FASTA version 1.7 suite of sequence comparison programs (Pearson, *et al.*, 1988; Pearson, 1990; program available from William R. Pearson, Department of Biological Chemistry, Box 440, Jordan Hall, Charlottesville, VA).

Those skilled in the art can determine appropriate parameters for measuring alignment, including selecting an algorithm (*e.g.* "Best Fit" or "BLASTX") needed to achieve maximal alignment over the sequences being compared [see also, Pearson, *et al.*, *Methods in Enzymol.* 266:227-258 (1996)].

Also included within the definition of prostate tumor antigens of the present invention are amino acid sequence variants. These variants fall into one or more of three classes: substitutional, insertional or deletional variants. These variants ordinarily are prepared by site specific mutagenesis of nucleotides in the DNA encoding the prostate tumor antigen, using cassette or PCR mutagenesis or other techniques well known in the art, to produce DNA encoding the variant, and thereafter expressing the DNA in recombinant cell culture. However, variant prostate tumor antigen fragments having up to about 100-150 residues may be prepared by *in vitro* synthesis using established techniques. Amino acid sequence variants are characterized by the predetermined nature of the variation, a feature that sets them apart from naturally occurring allelic or interspecies variation of the prostate tumor antigen amino acid sequence. The variants typically exhibit the same qualitative biological activity as the naturally occurring analogue, although variants can also be selected which have modified characteristics as will be more fully outlined below.

A "substitution" results from the replacement of one or more nucleotides or amino acids by different nucleotides or amino acids, respectively.

An "insertion" or "addition" is that change in a nucleotide or amino acid sequence which has resulted in the addition of one or more nucleotides or amino acid residues, respectively, as compared  
5 to the naturally occurring sequence.

A "deletion" is defined as a change in either nucleotide or amino acid sequence in which one or more nucleotides or amino acid residues, respectively, are absent.

While the site or region for introducing an amino acid sequence variation is predetermined, the change per se need not be predetermined. For example, in order to optimize the performance of  
10 a mutation at a given site, random mutagenesis may be conducted at the target codon or region and the expressed prostate tumor antigen variants screened for the optimal combination of desired activity. Techniques for making substitutions at predetermined sites in DNA having a known sequence are well known, for example, M13 primer mutagenesis and PCR mutagenesis. Screening of the mutants may be done directly by PCR, or following expression of the modified sequence using assays for prostate  
15 tumor antigen, for example, antibody detection studies may be done.

Amino acid substitutions are typically of single residues; insertions usually will be on the order of from about 1 to 20 amino acids, although considerably larger insertions may be tolerated. Deletions range from about 1 to about 20 residues, although in some cases deletions may be much larger.

20 Substitutions, deletions, insertions or any combination thereof may be used to arrive at a final derivative. Generally these changes are done on a few amino acids to minimize the alteration of the molecule. However, larger changes may be tolerated in certain circumstances.

Amino acid substitutions can be the result of replacing one amino acid with another amino acid having similar structural and/or chemical properties, such as the replacement of a leucine with  
25 a serine, *i.e.*, conservative amino acid replacements. Insertions or deletions may optionally be in the range of 1 to 5 amino acids.

The variation allowed with retention of biological activity may be determined by systematically making insertions, deletions or substitutions of amino acids in the sequence and testing the resulting variants for activity. Gene expression, may be measured by immunological methods, such as  
30 immunohistochemical staining of cells or tissue sections and assay of cell culture or body fluids, to quantitate directly the expression of the gene product. Antibodies useful for immunohistochemical staining and/or assay of sample tissues or fluids may be either monoclonal or polyclonal, and may be prepared against a native prostate tumor antigen, a synthetic peptide based on the DNA sequences provided herein or against a heterologous fusion protein which includes a prostate tumor specific  
35 antibody epitope. Examples prostate cancer antigens with diagnostic utility in antibody-based assays



include, but are not limited to, prostate-specific antigen (PSA, U.S. Patent Nos. 5,710,007; 5,614,372; 5,672,480 and others), prostate-specific membrane antigen (PSMA, U.S. Patent No. 5,538,866) and human prostatic glandular kallikrein (HK-2, U.S. Patent No. 5,516,639). Many diagnostic assays based on various different technologies routinely used by those of skill in the art  
5 have been developed for these molecules.

When small alterations in the characteristics of the prostate tumor antigen are desired, substitutions are generally made in accordance with known "conservative substitutions".

A "conservative substitution" refers to the substitution of an amino acid in one class by an amino acid in the same class, where a class is defined by common physicochemical amino acid side  
10 chain properties and high substitution frequencies in homologous proteins found in nature (as determined, *e.g.*, by a standard Dayhoff frequency exchange matrix or BLOSUM matrix). Six general classes of amino acid side chains, categorized as described above, include: Class I (Cys); Class II (Ser, Thr, Pro, Ala, Gly); Class III (Asn, Asp, Gln, Glu); Class IV (His, Arg, Lys); Class V (Ile, Leu, Val, Met); and Class VI (Phe, Tyr, Trp). For example, substitution of an Asp for another class  
15 III residue such as Asn, Gln, or Glu, is a conservative substitution.

A "non-conservative substitution" refers to the substitution of an amino acid in one class with an amino acid from another class; for example, substitution of an Ala, a class II residue, with a class III residue such as Asp, Asn, Glu, or Gln.

Substantial changes in function or immunological identity are made by selecting substitutions  
20 that are "non-conservative substitutions". For example, substitutions may be made which more significantly affect; the structure of the polypeptide backbone in the area of the alteration, for example the alpha-helical or beta-sheet structure, the charge or hydrophobicity of the molecule at the target site, or the bulk of the side chain. The substitutions which in general are expected to produce the greatest changes in the polypeptide's properties are those in which (a) a hydrophilic residue, *e.g.* seryl or threonyl, is substituted for (or by) a hydrophobic residue, *e.g.*, leucyl, isoleucyl, phenylalanyl, valyl or alanyl; (b) a cysteine or proline is substituted for (or by) any other residue; (c) a residue  
25 having an electropositive side chain, *e.g.*, lysyl, arginyl, or histidyl, is substituted for (or by) an electronegative residue, *e.g.*, glutamyl or aspartyl; or (d) a residue having a bulky side chain, *e.g.*, phenylalanine, is substituted for (or by) one not having a side chain, *e.g.*, glycine.

30 Prostate tumor antigen variants typically exhibit the same qualitative biological activity and will elicit the same immune response as the naturally-occurring analogue, although variants also are selected to modify the characteristics of the prostate tumor antigen, as needed. For example, glycosylation sites, and more particularly one or more O-linked or N-linked glycosylation sites may be altered or removed. Those skilled in the art will appreciate that amino acid changes may alter post-

translational processes of the prostate tumor antigen, such as changing the number or position of glycosylation sites or altering the membrane anchoring characteristics.

The variations can be made using methods known in the art such as oligonucleotide-mediated (site-directed) mutagenesis, alanine scanning, and PCR mutagenesis. Site-directed mutagenesis [Carter, *et al.*, *Nucl. Acids Res.* 13:4331 (1986); Zoller, *et al.*, *Nucl. Acids Res.* 10:6487 (1987)], cassette mutagenesis [Wells, *et al.*, *Gene* 34:315 (1985)], restriction selection mutagenesis [Wells, *et al.*, *Philos. Trans. R. Soc. London SerA* 317:415 (1986)] or other known techniques can be performed on the cloned DNA to produce the prostate tumor antigen-encoding variant DNA.

Also included with the definition of prostate tumor antigen proteins are other related prostate tumor antigen proteins. Thus, probe or degenerate polymerase chain reaction (PCR) primer sequences may be used to find other related proteins. Useful probe or primer sequences may be designed to: all or part of the prostate tumor antigen sequence, or sequences outside the coding region. As is generally known in the art, preferred PCR primers are from about 15 to about 35 nucleotides in length, with from about 20 to about 30 being preferred, and may contain inosine as needed. The conditions for the PCR reaction are generally known in the art.

#### B. Modifications of Prostate Tumor Antigens

Covalent modifications of a prostate tumor antigen are included within the scope of this invention. One type of covalent modification includes reacting targeted amino acid residues of a prostate tumor antigen with an organic derivatizing agent that is capable of reacting with selected side chains or the N-or C-terminal residues of a prostate tumor antigen polypeptide. Derivatization with bifunctional agents is useful, for instance, for crosslinking a prostate tumor antigen to a water-insoluble support matrix or surface. Commonly used crosslinking agents include, *e.g.*, 1,1-bis(diazoacetyl)-2-phenylethane, glutaraldehyde, N-hydroxysuccinimide esters, for example, esters with 4-azidosalicylic acid, homobifunctional imidoesters, including disuccinimidyl esters such as 3,3'-dithiobis(succinimidylpropionate), bifunctional maleimides such as bis-N-maleimido-1,8-octane and agents such as methyl-3-[(p-azidophenyl)dithio] propioimide.

Other modifications include deamidation of glutamyl and asparaginy residues to the corresponding glutamyl and aspartyl residues, respectively, hydroxylation of proline and lysine, phosphorylation of hydroxyl groups of seryl or threonyl residues, methylation of the  $\alpha$ -amino groups of lysine, arginine, and histidine side chains [T.E. Creighton, PROTEINS: STRUCTURE AND MOLECULAR PROPERTIES, W.H. Freeman & Co., San Francisco, pp. 79-86 (1983)], acetylation of the N-terminal amine, and amidation of any C-terminal carboxyl group.

Another type of covalent modification of a prostate tumor antigen polypeptide included within the scope of this invention comprises altering the native glycosylation pattern of the polypeptide,

namely modifying a native sequence prostate tumor antigen polypeptide by deleting one or more carbohydrate moieties from and/or adding one or more carbohydrate moieties to, the native sequence prostate tumor antigen polypeptide.

Addition of glycosylation sites to a prostate tumor antigen polypeptides may be accomplished  
5 by altering the amino acid sequence thereof. The alteration may be made, for example, by the addition of, or substitution by, one or more serine or threonine residues to the native sequence prostate tumor antigen polypeptide (for O-linked glycosylation sites). The prostate tumor antigen amino acid sequence may optionally be altered through changes at the DNA level, particularly by mutating the DNA encoding the prostate tumor antigen polypeptide at preselected bases such that codons are  
10 generated that will translate into the desired amino acids.

Another means of increasing the number of carbohydrate moieties on the prostate tumor antigen polypeptide is by chemical or enzymatic coupling of glycosides to the polypeptide. Such methods are described in the art, *e.g.*, in WO 87/05330 published 11 September 1987, and in Aplin and Wriston, *CRC Crit. Rev. Biochem.* pp. 259-306 (1981).

15 Removal of carbohydrate moieties present on the prostate tumor antigen polypeptide may be accomplished chemically or enzymatically or by mutational substitution of codons encoding for amino acid residues that serve as targets for glycosylation. In addition, carbohydrate moieties may be removed by enzymatic cleavage by the use of a variety of endo-and exo-glycosidases as described by Thotakura, *et al.*, *Meth. Enzymol.* 138:350 (1987) or by chemical deglycosylation techniques  
20 described, for example, in Hakimuddin, *et al.*, *Arch. Biochem. Biophys.* 259:52 (1987) and by Edge, *et al.*, *Anal. Biochem.* 118:131 (1981).

Another type of covalent modification of a prostate tumor antigen comprises linking the antigen to a non proteinaceous polymer, *e.g.*, polyethylene glycol, poly- propylene glycol, or polyoxyalkylenes, for example, as set forth in U.S. Patent No. 4,791,192.

25

C. Encoded Polypeptide Antigens

1. Expression of Prostate Tumor Antigens

The polynucleotide sequences described herein can be used in recombinant DNA molecules that direct the expression of the corresponding polypeptides in appropriate host cells. As discussed  
30 above, genetic code degeneracy dictates that other DNA sequences which encode substantially the same or a functionally equivalent amino acid sequence may be used to clone and express the identified polypeptides. Codons preferred by a particular host cell may be selected and substituted into the naturally occurring nucleotide sequences, to increase the rate and/or efficiency of expression.

The nucleic acid (*e.g.*, cDNA or genomic DNA) encoding the desired prostate tumor antigen  
35 polypeptide may be inserted into a replicable vector for cloning (amplification of the DNA), or for

expression. The polypeptide can be expressed recombinantly in any of a number of expression systems according to methods known in the art (Ausubel, *et al.*, 1990).

Appropriate host cells include yeast, bacteria, archebacteria, fungi, and insect and animal cells, including mammalian cells, for example primary cells, including stem cells, including, but not limited to bone marrow stem cells. More specifically, these include, but are not limited to, microorganisms such as bacteria transformed with recombinant bacteriophage, plasmid or cosmid DNA expression vectors, and yeast transformed with yeast expression vectors. Also included, are insect cells infected with a recombinant insect virus (such as baculovirus), and mammalian expression systems.

The nucleic acid sequence to be expressed may be inserted into the vector by a variety of procedures. In general, DNA is inserted into an appropriate restriction endonuclease site using techniques known in the art. Vector components generally include, but are not limited to, one or more of a signal sequence, an origin of replication, one or more marker genes, an enhancer element, a promoter, and a transcription termination sequence. Construction of suitable vectors containing one or more of these components employs standard ligation techniques which are known to the skilled artisan.

The prostate tumor antigen proteins of the present invention are produced by culturing a host cell transformed with an expression vector containing a nucleic acid encoding a prostate tumor antigen protein, under the appropriate conditions to induce or cause expression of the protein. The conditions appropriate for prostate tumor antigen protein expression will vary with the choice of the expression vector and the host cell, and will be easily ascertained by one skilled in the art through routine experimentation. For example, the use of constitutive promoters in the expression vector will require optimizing the growth and proliferation of the host cell, while the use of an inducible promoter requires the appropriate growth conditions for induction. In addition, in some embodiments, the timing of the harvest is important. For example, the baculoviral systems used in insect cell expression are lytic viruses, and thus harvest time selection can be crucial for product yield.

A host cell strain may be chosen for its ability to modulate the expression of the inserted sequences or to process the expressed protein in the desired fashion. Such modifications of the protein include, but are not limited to, acetylation, carboxylation, glycosylation, phosphorylation, lipidation and acylation. Post-translational processing which cleaves a "prepro" form of the protein may also be important for correct insertion, folding and/or function. By way of example, host cells such as CHO, HeLa, BHK, MDCK, 293, WI38, etc. have specific cellular machinery and characteristic mechanisms for such post-translational activities and may be chosen to ensure the correct modification and processing of the introduced, foreign protein. Of particular interest are *Drosophila melangaster* cells, *Saccharomyces cerevisiae* and other yeasts, *E. coli*, *Bacillus subtilis*, SF9 cells, C129 cells, 293

cells, Neurospora, BHK, CHO, COS, and HeLa cells, fibroblasts, Schwannoma cell lines, immortalized mammalian myeloid and lymphoid cell lines, Jukat cells, human cells and other primary cells.

The nucleic acid must be "operably linked" by placing it into a functional relationship with another nucleic acid sequence. For example, DNA for a presequence or secretory leader is operably  
5 linked to DNA for a polypeptide if it is expressed as a preprotein that participates in the secretion of the polypeptide; a promoter or enhancer is operably linked to a coding sequence if it affects the transcription of the sequence; or a ribosome binding site is operably linked to a coding sequence if it is positioned so as to facilitate translation. Generally, "operably linked" DNA sequences are contiguous, and, in the case of a secretory leader, contiguous and in reading phase. However,  
10 enhancers do not have to be contiguous. Linking is accomplished by ligation at convenient restriction sites. If such sites do not exist, the synthetic oligonucleotide adaptors or linkers are used in accordance with conventional practice.

Promoter sequences encode either constitutive or inducible promoters. The promoters may be either naturally occurring promoters or hybrid promoters. Hybrid promoters, which combine  
15 elements of more than one promoter, are also known in the art, and are useful in the present invention.

The expression vector may comprise additional elements, for example, the expression vector may have two replication systems, thus allowing it to be maintained in two organisms, for example in mammalian or insect cells for expression and in a procaryotic host for cloning and amplification.

20 Both expression and cloning vectors contain a nucleic acid sequence that enables the vector to replicate in one or more selected host cells. Such sequences are well known for a variety of bacteria, yeast, and viruses. The origin of replication from the plasmid pBR322 is suitable for most Gram-negative bacteria, the 2: plasmid origin is suitable for yeast, and various viral origins (SV40, polyoma, adenovirus, VSV or BPV) are useful for cloning vectors in mammalian cells.

25 Further, for integrating expression vectors, the expression vector contains at least one sequence homologous to the host cell genome, and preferably two homologous sequences which flank the expression construct. The integrating vector may be directed to a specific locus in the host cell by selecting the appropriate homologous sequence for inclusion in the vector. Constructs for integrating vectors are well known in the art.

30 Preferably, the expression vector contains a selectable marker gene to allow the selection of transformed host cells. Selection genes are well known in the art and will vary with the host cell used.

Expression and cloning vectors will typically contain a selection gene, also termed a selectable marker. Typical selection genes encode proteins that (a) confer resistance to antibiotics or other  
35 toxins, *e.g.*, ampicillin, neomycin, methotrexate, or tetracycline, (b) complement auxotrophic

deficiencies, or (c) supply critical nutrients not available from complex media, *e.g.*, the gene encoding D-alanine racemase for *Bacilli*.

Host cells transformed with a nucleotide sequence encoding a prostate tumor antigen may be cultured under conditions suitable for the expression and recovery of the encoded protein from cell culture. The protein produced by a recombinant cell may be secreted, membrane-bound, or contained intracellularly depending on the sequence and/or the vector used. As will be understood by those of skill in the art, expression vectors containing polynucleotides encoding the prostate tumor antigen can be designed with signal sequences which direct secretion of the prostate tumor antigen through a prokaryotic or eukaryotic cell membrane.

The desired prostate tumor antigen polypeptide may be produced recombinantly not only directly, but also as a fusion polypeptide with a heterologous polypeptide, which may be a signal sequence or other polypeptide having a specific cleavage site at the N-terminus of the mature protein or polypeptide. In general, the signal sequence may be a component of the vector, or it may be a part of the prostate tumor antigen-encoding DNA that is inserted into the vector. The signal sequence may be a prokaryotic signal sequence selected, for example, from the group of the alkaline phosphatase, penicillinase, lpp, or heat-stable enterotoxin II leaders. For yeast secretion the signal sequence may be, *e.g.*, the yeast invertase leader, alpha factor leader (including *Saccharomyces* and *Kluyveromyces* " $\alpha$ -factor leaders, the latter described in U.S. Patent No. 5,010,182), or acid phosphatase leader, the *C. albicans* glucoamylase leader (EP 362,179 published 4 April 1990), or the signal described in WO 90/13646 published 15 November 1990. In mammalian cell expression, mammalian signal sequences may be used to direct secretion of the protein, such as signal sequences from secreted polypeptides of the same or related species, as well as viral secretory leaders.

According to the expression system selected, the coding sequence is inserted into an appropriate vector, which in turn may require the presence of certain characteristic "control elements" or "regulatory sequences." Appropriate constructs are known generally in the art (Ausubel, *et al.*, 1990) and, in many cases, are available from commercial suppliers such as Invitrogen (San Diego, CA), Stratagene (La Jolla, CA), Gibco BRL (Rockville, MD) or Clontech (Palo Alto, CA).

a. Expression in Bacterial Systems. Transformation of bacterial cells may be achieved using an inducible promoter such as the hybrid lacZ promoter of the "BLUESCRIPT" Phagemid (Stratagene, La Jolla, CA) or "pSPORT1" (Gibco BRL, Rockville, MD). In addition, a number of expression vectors may be selected for use in bacterial cells to produce cleavable fusion proteins that can be easily detected and/or purified, including, but not limited to "BLUESCRIPT" ( $\beta$ -galactosidase; Stratagene, La Jolla, CA) or pGEX (glutathione S-transferase; Promega, Madison, WI).

A suitable bacterial promoter is any nucleic acid sequence capable of binding bacterial RNA polymerase and initiating the downstream (3') transcription of the coding sequence of the prostate tumor antigen gene into mRNA. A bacterial promoter has a transcription initiation region which is usually placed proximal to the 5' end of the coding sequence. This transcription initiation region typically includes an RNA polymerase binding site and a transcription initiation site. Sequences encoding metabolic pathway enzymes provide particularly useful promoter sequences. Examples include promoter sequences derived from sugar metabolizing enzymes, such as galactose, lactose and maltose, and sequences derived from biosynthetic enzymes such as tryptophan. Promoters from bacteriophage may also be used and are known in the art. In addition, synthetic promoters and hybrid promoters are also useful; for example, the *tac* promoter is a hybrid of the *trp* and *lac* promoter sequences. Furthermore, a bacterial promoter can include naturally occurring promoters of non-bacterial origin that have the ability to bind bacterial RNA polymerase and initiate transcription. An efficient ribosome binding site is also desirable.

The expression vector may also include a signal peptide sequence that provides for secretion of the prostate tumor antigen protein in bacteria. The signal sequence typically encodes a signal peptide comprised of hydrophobic amino acids which direct the secretion of the protein from the cell, as is well known in the art. The protein is either secreted into the growth media (gram-positive bacteria) or into the periplasmic space, located between the inner and outer membrane of the cell (gram-negative bacteria). The bacterial expression vector may also include a selectable marker gene to allow for the selection of bacterial strains that have been transformed. Suitable selection genes include drug resistance genes such as ampicillin, chloramphenicol, erythromycin, kanamycin, neomycin and tetracycline. Selectable markers also include biosynthetic genes, such as those in the histidine, tryptophan and leucine biosynthetic pathways.

When large quantities of prostate tumor antigen are needed, e.g., for the induction of antibodies, vectors which direct high level expression of fusion proteins that are readily purified may be desirable. Such vectors include, but are not limited to, multifunctional *E. coli* cloning and expression vectors such as BLUESCRIPT® (Stratagene, La Jolla, CA), in which the prostate tumor antigen coding sequence may be ligated into the vector in-frame with sequences for the amino-terminal Met and the subsequent 7 residues of beta-galactosidase so that a hybrid protein is produced; pIN vectors [Van Heeke and Schuster, *J. Biol. Chem.* 264:5503-5509 1989]; pET vectors (Novagen, Madison, WI); and the like.

Expression vectors for bacteria include the various components set forth above, and are well known in the art. Examples include vectors for *Bacillus subtilis*, *E. coli*, *Streptococcus cremoris*, and *Streptococcus lividans*, among others. Bacterial expression vectors are transformed into bacterial host

cells using techniques well known in the art, such as calcium chloride mediated transfection, electroporation, and others.

b. Expression in Yeast. Yeast expression systems are well known in the art, and include expression vectors for *Saccharomyces cerevisiae*, *Candida albicans* and *C. maltosa*, *Hansenula polymorpha*, *Kluyveromyces fragilis* and *K. lactis*, *Pichia guillermondii* and *P. pastoris*, *Schizosaccharomyces pombe*, and *Yarrowia lipolytica*. Examples of suitable promoters for use in yeast hosts include the promoters for 3-phosphoglycerate kinase [Hitzeman, *et al.*, *J. Biol. Chem.* **255**:2073 (1980)] or other glycolytic enzymes [Hess, *et al.*, *J. Adv. Enzyme Reg.* **7**:149 (1968); Holland, *Biochemistry* **17**:4900 (1978)], such as enolase, glyceraldehyde-3-phosphate dehydrogenase, hexokinase, pyruvate decarboxylase, phosphofructokinase, glucose- 6-phosphate isomerase, 3-phosphoglycerate mutase, pyruvate kinase, triosephosphate isomerase, phosphoglucose isomerase, alpha factor, the ADH2/GAPDH promoter, glucokinase alcohol oxidase, and PGH. [See, for example, Ausubel, *et al.*, 1990; Grant, *et al.*, *Methods in Enzymology* **153**:516-544, (1987)].

Other yeast promoters, which are inducible have the additional advantage of transcription controlled by growth conditions, include the promoter regions for alcohol dehydrogenase 2, isocytochrome C, acid phosphatase, degradative enzymes associated with nitrogen metabolism, metallothionein, glyceraldehyde-3-phosphate dehydrogenase, and enzymes responsible for maltose and galactose utilization. Suitable vectors and promoters for use in yeast expression are further described in EP 73,657. Yeast selectable markers include ADE2, HIS4, LEU2, TRP1, and ALG7, which confers resistance to tunicamycin; the neomycin phosphotransferase gene, which confers resistance to G418; and the CUP1 gene, which allows yeast to grow in the presence of copper ions.

Yeast expression vectors can be constructed for intracellular production or secretion of a prostate tumor antigen from the DNA encoding the prostate tumor antigen of interest. For example, a selected signal peptide and the appropriate constitutive or inducible promoter may be inserted into suitable restriction sites in the selected plasmid for direct intracellular expression of the prostate tumor antigen polypeptide. For secretion of the prostate tumor antigen, DNA encoding the prostate tumor antigen polypeptide can be cloned into the selected plasmid, together with DNA encoding the promoter, the yeast alpha-factor secretory signal/leader sequence, and linker sequences (as needed), for expression of the prostate tumor antigen polypeptide.

Yeast cells, can then be transformed with the expression plasmids described above, and cultured in an appropriate fermentation media. The protein produced by such transformed yeast can then be concentrated by precipitation with 10% trichloroacetic acid and analyzed following separation by SDS-PAGE and staining of the gels with Coomassie Blue stain.



The recombinant prostate tumor antigen can subsequently be isolated and purified from the fermentation medium by techniques known to those of skill in the art.

c. Expression in Mammalian Systems. The prostate tumor antigen proteins may  
5 be expressed in mammalian cells. Mammalian expression systems are known in the art, and include retroviral vector mediated expression systems. Mammalian host cells may be transformed with any of a number of different viral-based expression systems, such as adenovirus, where the coding region can be ligated into an adenovirus transcription/translation complex consisting of the late promoter and tripartite leader sequence. Insertion in a nonessential E1 or E3 region of the viral genome results in  
10 a viable virus capable of expression of the polypeptide of interest in infected host cells.

A preferred expression vector system is a retroviral vector system such as is generally described in PCT/US97/01019 and PCT/US97/01048, both of which are hereby expressly incorporated by reference.

Suitable mammalian expression vectors contain a mammalian promoter which is any DNA  
15 sequence capable of binding mammalian RNA polymerase and initiating the downstream (3') transcription of a coding sequence for prostate tumor antigen protein into mRNA. A promoter will have a transcription initiating region, which is usually placed proximal to the 5' end of the coding sequence, and a TATA box, using a located 25-30 base pairs upstream of the transcription initiation site. The TATA box is thought to direct RNA polymerase II to begin RNA synthesis at the correct  
20 site. A mammalian promoter will also contain an upstream promoter element (enhancer element), typically located within 100 to 200 base pairs upstream of the TATA box. An upstream promoter element determines the rate at which transcription is initiated and can act in either orientation. Of particular use as mammalian promoters are the promoters from mammalian viral genes, since the viral genes are often highly expressed and have a broad host range.

25 Examples include promoters obtained from the genomes of viruses such as polyoma virus, fowlpox virus (UK 2,211,504 published 5 July 1989), adenovirus (such as Adenovirus 2), bovine papilloma virus, avian sarcoma virus, cytomegalovirus, a retrovirus, hepatitis-B virus and Simian Virus 40 (SV40), from heterologous mammalian promoters, *e.g.*, the actin promoter or an immunoglobulin promoter, and from heat-shock promoters, provided such promoters are compatible  
30 with the host cell systems.

Transcription of a DNA encoding a prostate tumor antigen polypeptide by higher eukaryotes may be increased by inserting an enhancer sequence into the vector. Enhancers are cis-acting elements of DNA, usually about from 10 to 300 bp, that act on a promoter to increase its transcription. Many enhancer sequences are now known from mammalian genes (globin, elastase, albumin, " $\alpha$ -fetoprotein,  
35 and insulin). Typically, however, one will use an enhancer from a eukaryotic cell virus. Examples

include the SV40 enhancer, the cytomegalovirus early promoter enhancer, the polyoma enhancer on the late side of the replication origin, and adenovirus enhancers. The enhancer is preferably located at a site 5' from the promoter.

5 In general, the transcription termination and polyadenylation sequences recognized by mammalian cells are regulatory regions located 3' to the translation stop codon and thus, together with the promoter elements, flank the coding sequence. The 3' terminus of the mature mRNA is formed by site-specific post-translational cleavage and polyadenylation. Examples of transcription terminator and polyadenylation signals include those derived from SV40.

10 Long-term, high-yield production of recombinant proteins can be effected in a stable expression system. Expression vectors which contain viral origins of replication or endogenous expression elements and a selectable marker gene may be used for this purpose. Appropriate vectors containing selectable markers for use in mammalian cells are readily available commercially and are known to persons skilled in the art. Examples of such selectable markers include, but are not limited to herpes simplex virus thymidine kinase and adenine phosphoribosyltransferase for use in tk- or hprr-  
15 cells, respectively.

The methods of introducing exogenous nucleic acid into mammalian hosts, as well as other hosts, is well known in the art, and will vary with the host cell used. Techniques include dextran-mediated transfection, calcium phosphate precipitation, polybrene mediated transfection, protoplast fusion, electroporation, viral infection, encapsulation of the polynucleotide(s) in liposomes, and direct  
20 microinjection of the DNA into nuclei.

d. Expression in Insect Cells. Prostate tumor antigen polypeptides may also be produced in insect cells. Expression vectors for the transformation of insect cells, and in particular, baculovirus-based expression vectors, are well known in the art. In one such system, the prostate  
25 tumor antigen-encoding DNA is fused upstream of an epitope tag contained within a baculovirus expression vector. *Autographa californica* nuclear polyhedrosis virus (AcNPV) is used as a vector to express foreign genes in *Spodoptera frugiperda* Sf9 cells or in *Trichoplusia* larvae. The prostate tumor antigen-encoding sequence is cloned into a nonessential region of the virus, such as the polyhedrin gene, and placed under control of the polyhedrin promoter. Successful insertion of a  
30 prostate tumor antigen-encoding sequence will render the polyhedrin gene inactive and produce recombinant virus lacking coat protein coat. The recombinant viruses are then used to infect *S. frugiperda* cells or *Trichoplusia* larvae in which the prostate tumor antigen is expressed [Smith, *et al.*, *J. Virol.* **46**:584 (1994); Engelhard, *et al.*, *Proc. Nat. Acad. Sci.* **91**:3224-3227 (1994)].

Suitable epitope tags for fusion to the prostate tumor antigen-encoding DNA include poly-his  
35 tags and immunoglobulin tags (like Fc regions of IgG). A variety of plasmids may be employed,

including commercially available plasmids such as pVL1393 (Novagen, Madison, WI). Briefly, the prostate tumor antigen-encoding DNA or the desired portion of the prostate tumor antigen-encoding DNA is amplified by PCR with primers complementary to the 5' and 3' regions. The 5' primer may incorporate flanking restriction sites. The PCR product is then digested with the selected restriction enzymes and subcloned into an expression vector.

Recombinant baculovirus is generated by co-transfecting the above plasmid and BaculoGold™ virus DNA (Pharmingen, San Diego, CA) into *Spodoptera frugiperda* ("Sf9") cells (ATCC CRL 1711) using lipofectin (commercially available from Gibco-BRL, Rockville, MD), or other methods known to those of skill in the art. Virus is produced by day 4-5 of culture in Sf9 cells at 28°C, and used for further amplifications. Procedures are performed as further described in O'Reilly, *et al.*, BACULOVIRUS EXPRESSION VECTORS: A LABORATORY MANUAL, Oxford University Press (1994).

Extracts may be prepared from recombinant virus-infected Sf9 cells as described in Rupert, *et al.*, *Nature* 362:175-179 (1993).

Alternatively, expressed epitope-tagged prostate tumor antigen polypeptides can be purified by affinity chromatography, or for example, purification of an IgG-tagged (or Fc-tagged) prostate tumor antigen polypeptide can be performed using chromatography techniques, including Protein A or protein G column chromatography.

#### D. Evaluation of Gene Expression

Gene expression may be evaluated in a sample directly, for example, by standard techniques known to those of skill in the art, *e.g.*, Southern blotting for DNA detection, Northern blotting to determine the transcription of mRNA, dot blotting (DNA or RNA), or *in situ* hybridization, using an appropriately labeled probe, based on the sequences provided herein. Alternatively, antibodies may be used in assays for detection of nucleic acids, such as specific duplexes, including DNA duplexes, RNA duplexes, and DNA-RNA hybrid duplexes or DNA-protein duplexes. Such antibodies may be labeled and the assay carried out where the duplex is bound to a surface, so that upon the formation of duplex on the surface, the presence of antibody bound to the duplex can be detected.

Gene expression, alternatively, may be measured by immunohistochemical staining of cells or tissue sections and assay of cell culture or body fluids, to directly evaluate the expression of prostate tumor antigens. Antibodies useful for such immunological assays may be either monoclonal or polyclonal, and may be prepared against a native sequence prostate tumor antigen based on the DNA sequences provided herein.

### 1. Purification of Expressed Protein

Expressed prostate tumor antigen polypeptides may be purified or isolated after expression, using any of a variety of methods known to those skilled in the art. The appropriate technique will vary depending upon what other components are present in the sample. Contaminant components that are removed by isolation or purification are materials that would typically interfere with diagnostic or therapeutic uses for the polypeptide, and may include enzymes, hormones, and other solutes. The purification step(s) selected will depend, for example, on the nature of the production process used and the particular prostate tumor antigen polypeptide produced.

A prostate tumor antigen polypeptide or protein may be recovered from culture medium or from host cell lysates. If membrane-bound, it can be released from the membrane using a suitable detergent solution (*e.g.* Triton-X 100) or by enzymatic cleavage. Alternatively, cells employed in expression of prostate tumor antigen polypeptides can be disrupted by various physical or chemical means, such as freeze-thaw cycling, sonication, mechanical disruption, or by use of cell lysing agents.

Exemplary purification methods include, but are not limited to, ion-exchange column chromatography; chromatography using silica gel or a cation-exchange resin such as DEAE; gel filtration using, for example, Sephadex G-75; protein A Sepharose columns to remove contaminants such as IgG; chromatography using metal chelating columns to bind epitope-tagged forms of the prostate tumor antigen polypeptide; ethanol precipitation; reverse phase HPLC; chromatofocusing; SDS-PAGE; and ammonium sulfate precipitation. Ordinarily, an isolated prostate tumor antigen polypeptide will be prepared by at least one purification step. For example, the prostate tumor antigen protein may be purified using a standard anti-prostate tumor antigen antibody column. Ultrafiltration and dialysis techniques, in conjunction with protein concentration, are also useful (see, for example, Scopes, R., PROTEIN PURIFICATION, Springer-Verlag, NY, 1982). The degree of purification necessary will vary depending on the use of the prostate tumor antigen. In some instances no purification will be necessary.

Once expressed and purified as needed, the prostate tumor antigen proteins and nucleic acids of the present invention are useful in a number of applications, as detailed below.

### 2. Labeling of Expressed Protein

The nucleic acids, proteins and antibodies of the invention may be labeled. By labeled herein is meant that a compound has at least one element, isotope or chemical compound attached to enable the detection of the compound. In general, labels fall into three classes: a) isotopic labels, which may be radioactive or heavy isotopes; b) immune labels, which may be antibodies or antigens; and c) colored or fluorescent dyes. The labels may be incorporated into the compound at any position that

does not interfere with the biological activity or characteristic of the compound which is being detected.

### 3. Prostate Tumor Antigen Fusion Proteins

5       The prostate tumor antigens of the present invention may also be modified in a way to form chimeric molecules comprising a prostate tumor antigen fused to another, heterologous polypeptide or amino acid sequence. The term "fusion protein" used herein refers to a chimeric polypeptide comprising a prostate tumor antigen polypeptide, or domain sequence thereof, fused to a "targeting polypeptide". The targeting polypeptide has enough residues to facilitate targeting to a particular cell  
10   type or receptor, yet is short enough such that it does not interfere with the biological function of the prostate tumor antigen polypeptide. The targeting polypeptide preferably is also fairly unique so that the fusion protein does not substantially cross-react with other cell types or receptors. Suitable targeting polypeptides generally have at least about 10 amino acid residues and usually between from about 10 to about 500 amino acid residues. Preferred targeting polypeptides have from about 20 to  
15   about 200 amino acid residues.

      The fusion protein may also comprises a fusion of a prostate tumor antigen with a tag polypeptide which provides an epitope to which an anti-tag antibody can selectively bind. The epitope tag is generally placed at the amino-or carboxyl-terminus of the prostate tumor antigen. Such epitope-tagged forms of a prostate tumor antigen can be detected using an antibody against the tag polypeptide.  
20   Also, provision of the epitope tag enables the prostate tumor antigen to be readily purified by using an anti-tag antibody or another type of affinity matrix that binds to the epitope tag. Alternatively, the fusion protein may comprise a fusion of a prostate tumor antigen with an immunoglobulin or a particular region of an immunoglobulin. For a bivalent form of the chimeric molecule, such a fusion could be to the Fc region of an IgG molecule or, for example, GM-CSF. Preferred fusion proteins  
25   include, but are not limited to, molecules that facilitate immune targeting of the prostate tumor antigen.

      The prostate tumor antigen fusion protein may be made for various other purposes using techniques well known in the art. For example, for the creation of antibodies, if the desired epitope is small, a partial or complete prostate tumor antigen protein may be fused to a carrier protein to form  
30   an immunogen. Alternatively, the prostate tumor antigen protein may be made as a fusion protein to increase the ability of the antigen to stimulate cellular and/or humoral (antibody-based) immune responses, or for other reasons.

E. Anti-prostate Tumor Antigen Antibodies

The present invention further provides anti-prostate tumor antigen antibodies. The antibodies of the present invention include polyclonal, monoclonal, humanized, bispecific, and heteroconjugate antibodies.

5

1. Polyclonal Antibodies

The anti-prostate tumor antigen antibodies of the present invention may be polyclonal antibodies. Methods of preparing polyclonal antibodies are known to the skilled artisan. Such polyclonal antibodies can be produced in a mammal, for example, following one or more injections of an immunizing agent, and preferably, an adjuvant. Typically, the immunizing agent and/or adjuvant will be injected into the mammal by a series of subcutaneous or intraperitoneal injections. The immunizing agent may include a prostate tumor antigen or a fusion protein thereof. It may be useful to conjugate the antigen to a protein known to be immunogenic in the mammal being immunized. Examples of such immunogenic proteins include, but are not limited to, keyhole limpet hemocyanin (KLH), serum albumin, bovine thyroglobulin, and soybean trypsin inhibitor. Adjuvants include, for example, Freund's complete adjuvant and MPL-TDM adjuvant (monophosphoryl Lipid A, synthetic trehalose dicorynomycolate). The immunization protocol may be determined by one skilled in the art based on standard protocols or by routine experimentation.

20

2. Monoclonal Antibodies

Alternatively, the anti-prostate tumor antigen antibodies may be monoclonal antibodies. Monoclonal antibodies may be produced by hybridomas, wherein a mouse, hamster, or other appropriate host animal, is immunized with an immunizing agent to elicit lymphocytes that produce or are capable of producing antibodies that will specifically bind to the immunizing agent [Kohler and Milstein, *Nature* 256:495 (1975)]. Alternatively, the lymphocytes may be immunized *in vitro*.

25

The immunizing agent will typically include the prostate tumor antigen or a fusion protein thereof. Generally, spleen cells or lymph node cells are used if non-human mammalian sources are desired, or peripheral blood lymphocytes ("PBLs") are used if cells of human origin. The lymphocytes are fused with an immortalized cell line using a suitable fusing agent, such as polyethylene glycol, to produce a hybridoma cell [Goding, MONOCLONAL ANTIBODIES: PRINCIPLES AND PRACTICE, Academic Press, pp. 59-103 (1986)]. In general, immortalized cell lines are transformed mammalian cells, for example, myeloma cells of rat, mouse, bovine or human origin. The hybridoma cells are cultured in a suitable culture medium that preferably contains one or more substances that inhibit the growth or survival of unfused, immortalized cells. For example, if the parental cells lack the enzyme hypoxanthine guanine phosphoribosyl transferase (HGPRT), the culture

35

medium for the hybridomas typically will include hypoxanthine, aminopterin, and thymidine (HAT), substances which prevent the growth of HGPRT-deficient cells.

Preferred immortalized cell lines are those that fuse efficiently, support stable high level production of antibody, and are sensitive to a medium such as HAT medium. More preferred  
5 immortalized cell lines are murine or human myeloma lines, which can be obtained, for example, from the American Type Culture Collection (ATCC), Rockville, Maryland. Human myeloma and mouse-human heteromyeloma cell lines also have been described for the production of human monoclonal antibodies [Kozbor, *J. Immunol.* 133:3001 (1984); Brodeur, *et al.*, MONOCLONAL ANTIBODY PRODUCTION TECHNIQUES AND APPLICATIONS, Marcel Dekker, Inc., New York, pp. 51-63 (1987)].

10 The culture medium (supernatant) in which the hybridoma cells are cultured can be assayed for the presence of monoclonal antibodies directed against a prostate tumor antigen. Preferably, the binding specificity of monoclonal antibodies present in the hybridoma supernatant is determined by immunoprecipitation or by an *in vitro* binding assay, such as radio-immunoassay (RIA) or enzyme-linked immunoabsorbent assay (ELISA). Appropriate techniques and assays are known in the art.  
15 The binding affinity of the monoclonal antibody can, for example, be determined by the Scatchard analysis of Munson and Pollard, *Anal. Biochem.* 107:220 (1980).

After the desired antibody-producing hybridoma cells are identified, the cells may be cloned by limiting dilution procedures and grown by standard methods [Goding, 1986]. Suitable culture media for this purpose include, for example, Dulbecco's Modified Eagle's Medium and RPMI-1640  
20 medium. Alternatively, the hybridoma cells may be grown *in vivo* as ascites in a mammal.

The monoclonal antibodies secreted by selected clones may be isolated or purified from the culture medium or ascites fluid by immunoglobulin purification procedures routinely used by those of skill in the art such as, for example, protein A-Sepharose, hydroxyl-apatite chromatography, gel electrophoresis, dialysis, or affinity chromatography.

25 The monoclonal antibodies may also be made by recombinant DNA methods, such as those described in U.S. Patent No. 4,816,567. DNA encoding the monoclonal antibodies of the invention can be isolated from the prostate tumor antigen-specific hybridoma cells and sequenced, *e.g.*, by using oligonucleotide probes that are capable of binding specifically to genes encoding the heavy and light chains of murine antibodies. Once isolated, the DNA may be inserted into an expression vector,  
30 which is then transfected into host cells such as simian COS cells, Chinese hamster ovary (CHO) cells, or myeloma cells that do not otherwise produce immunoglobulin protein, to obtain the synthesis of monoclonal antibodies in the recombinant host cells. The DNA also may be modified, for example, by substituting the coding sequence for the human heavy and light chain constant domains in place of the homologous murine sequences [Morrison, *et al. Proc. Nat. Acad. Sci.* 81:6851- 6855 (1984);  
35 Neuberger, *et al. Nature* 312:604-608 (1984); Takeda, *et al., Nature* 314:452-454 (1985)], or by

covalently joining to the immunoglobulin coding sequence all or part of the coding sequence for a non-immunoglobulin polypeptide. The non-immunoglobulin polypeptide can be substituted for the constant domains of an antibody of the invention, or can be substituted for the variable domains of one antigen-combining site of an antibody of the invention to create a chimeric bivalent antibody.

5       The antibodies may also be monovalent antibodies. Methods for preparing monovalent antibodies are well known in the art. For example, *in vitro* methods are suitable for preparing monovalent antibodies. Digestion of antibodies to produce fragments thereof, particularly, Fab fragments, can be accomplished using routine techniques known in the art.

### 10       3.     Humanized Antibodies

The anti-prostate tumor antigen antibodies of the invention may further comprise humanized antibodies or human antibodies. The term "humanized antibody" refers to humanized forms of non-human (*e.g.*, murine) antibodies that are chimeric antibodies, immunoglobulin chains or fragments thereof (such as Fv, Fab, Fab', F(ab')<sub>2</sub> or other antigen-binding partial sequences of antibodies) which  
15       contain some portion of the sequence derived from non-human antibody. Humanized antibodies include human immunoglobulins in which residues from a complementary determining region (CDR) of the human immunoglobulin are replaced by residues from a CDR of a non-human species such as mouse, rat or rabbit having the desired binding specificity, affinity and capacity. In general, the humanized antibody will comprise substantially all of at least one, and generally two, variable  
20       domains, in which all or substantially all of the CDR regions correspond to those of a non-human immunoglobulin and all or substantially all of the FR regions are those of a human immunoglobulin consensus sequence. The humanized antibody optimally also will comprise at least a portion of an immunoglobulin constant region (Fc), typically that of a human immunoglobulin [Jones, *et al.*, *Nature* 321:522-525 (1986) and Presta, *Curr. Op. Struct. Biol.* 2:593-596 (1992)].

25       Methods for humanizing non-human antibodies are well known in the art. Generally, a humanized antibody has one or more amino acids introduced into it from a source which is non-human in order to more closely resemble a human antibody, while still retaining the original binding activity of the antibody. Methods for humanization of antibodies are further detailed in Jones, *et al.*, *Nature* 321:522-525 (1986); Riechmann, *et al.*, *Nature* 332:323-327 (1988); and Verhoeyen, *et al.*, *Science*  
30       239:1534-1536 (1988).

Such "humanized" antibodies are chimeric antibodies in that substantially less than an intact human variable domain has been substituted by the corresponding sequence from a non-human species.



#### 4. Heteroconjugate Antibodies

Heteroconjugate antibodies which comprise two covalently joined antibodies, are also within the scope of the present invention. Heteroconjugate antibodies may be prepared *in vitro* using known methods in synthetic protein chemistry, including those involving crosslinking agents. For example, immunotoxins may be prepared using a disulfide exchange reaction or by forming a thioether bond.

#### 5. Bispecific Antibodies

Bispecific antibodies have binding specificities for at least two different antigens. Such antibodies are monoclonal, and preferably human or humanized. One of the binding specificities of a bispecific antibody of the present invention is for a prostate tumor antigen, and the other one is preferably for a cell-surface protein or receptor or receptor subunit.

Methods for making bispecific antibodies are known in the art, and in general, the recombinant production of bispecific antibodies is based on the co-expression of two immunoglobulin heavy-chain/light-chain pairs in hybridoma cells, where the two heavy chains have different specificities [Milstein and Cuello, *Nature* 305:537-539 (1983)]. Given that the random assortment of immunoglobulin heavy and light chains results in production of potentially ten different antibody molecules by the hybridomas, purification of the correct molecule usually requires some sort of affinity purification, *e.g.* affinity chromatography.

### 20 III. Utility

#### A. Polynucleotides

Polynucleotide sequences (or the complement thereof) which encode prostate tumor antigen polypeptides have various applications, including uses as hybridization probes, in chromosome and gene mapping, and in the generation of anti-sense RNA and DNA. In addition, prostate tumor antigen-encoding nucleic acids are useful as targets for pharmaceutical intervention, *e.g.* for the development of DNA vaccines, and for the preparation of prostate tumor antigen polypeptides by recombinant techniques, as described herein. The polynucleotides described herein, including sequence variants thereof, can be used in diagnostic assays, particularly for the detection of tumor cells. An important feature of the present invention is that the described sequences are currently recognized as specific to prostate tumor cells, but may also be characteristic of other tumor cells as well. Accordingly, diagnostic methods based on detecting the presence of such polynucleotides in body fluids or tissue samples are a feature of the present invention.

Examples of nucleic acid based diagnostic assays in accordance with the present invention include, but are not limited to, hybridization assays, *e.g.*, *in situ* hybridization, and PCR-based assays. Polynucleotides, including extended length polynucleotides, sequence variants and fragments thereof,

as described herein, may be used to generate hybridization probes or PCR primers for use in such assays. Such probes and primers will be capable of detecting polynucleotide sequences, including genomic sequences, that are similar, or complementary to, the tumor-specific polynucleotides described herein.

5 Hybridization probes can be used, for example, in performing *in situ* hybridization on tissue samples, such as fixed or frozen tissue sections prepared on microscopic slides or suspended cells. Briefly, a labeled DNA or RNA probe is allowed to bind its DNA or RNA target sample in the tissue section on a prepared microscopic, under controlled conditions. Generally, dsDNA probes consisting of the DNA of interest cloned into a plasmid or bacteriophage DNA vector are used for this purpose, 10 although ssDNA or ssRNA probes may also be used. Probes are generally oligonucleotides between about 15 and 40 nucleotides in length. Alternatively, the probes can be polynucleotide probes generated by PCR random priming primer extension or *in vitro* transcription of RNA from plasmids (riboprobes). These latter probes are typically several hundred base pairs in length. The probes can be labeled by any of a number of methods, including fluorescent tags, enzymes or radioactive 15 moieties, according to methods well known in the art. The particular detection method will correspond to the type of label utilized on the probe (*e.g.*, autoradiography, X-ray detection, fluorescent or visual microscopic analysis, as appropriate). The reaction can be further amplified *in situ* using immunocytochemical techniques directed against the label of the detector molecule used, such antibodies directed to a fluorescein moiety present on a fluorescently labeled probe, or against 20 avidin, or marker enzymes (peroxidase, alkaline phosphatase). Specific labeling and *in situ* detection methods can be found, for example, in Howard, G.C., Ed., METHODS IN NONRADIOACTIVE DETECTION, Appleton & Lange, Norwalk, CT, (1993), herein incorporated by reference.

One preferred assay for detecting prostate tumor cells utilizes the subject polynucleotides, or fragments thereof, as primers in a PCR-based assay. According to the assay, nucleic acids present 25 in a test tissue or cell sample are amplified by polymerase chain reaction (PCR) using two primers consisting of at least 15 nucleotides derived from one or more of a group consisting of SEQ ID NOs:1-8 and 14, including primers derived from variants and/or extensions of such sequences, as described herein. Amplification products are detected in the sample by a method that is appropriate to the particular label used to label the amplification products, according to methods as described in 30 U.S. Patent No. 4,683,195. For use in PCR detection methods, such as PCR *in situ* hybridization, PCR primers are selected to be at least 15 nucleotides in length, and preferably between about 15 and 30 nucleotides in length, and are selected from the DNA molecule of interest, according to methods known in the art. While such primers can be selected from within the sequences identified as SEQ ID NO:1 to SEQ ID NO:8 and SEQ ID NOs:14, herein, it may also be desirable to select sequences 35 that encompass the longer nucleotide sequences identified in accordance with Section IIA2, above.

Preferably, the probes are selected such that the two hybridization sites are separated by between about 100-1,000 nucleotides (occasionally up to about 10,000 nucleotides).

5 PCR *in situ* hybridization of tissue sections and/or cell samples provides a highly sensitive detection method for rare cell types in fixed cell or tissue samples. The PCR *in situ* hybridization detection method is carried out in accordance with methods that are known in the art, *e.g.*, Nuovo, G.J., PCR *in situ* HYBRIDIZATION: PROTOCOLS AND APPLICATIONS, Raven Press, NY, 1992; U.S. Patent No. 5,538,871, both of which are incorporated herein by reference.

10 Briefly, a cell sample (tissue on microscopic slide, pelleted cell suspension) is fixed using a common fixative preparation, such as buffered formalin, formaldehyde or the like. Proteinase or detergent treatment is favored following fixation, to increase cell permeability to reagents. The PCR reaction is carried out *in situ* by polymerase chain reaction (PCR) using two primers. As discussed above, the primers are designed to selectively amplify one or more of the nucleotide sequences described herein, and particularly sequences described as SEQ ID NO:1 to SEQ ID NO:8 and SEQ ID NO:14. The amplification reaction mixture contains, in addition to the target nucleotide sample  
15 and the primers, a thermostable DNA polymerase, such as a polymerase derived from *Thermus aquaticus* (Taq polymerase, U.S. Patent 4,889,818), and a sufficient quantity of the four standard deoxyribonucleotides (dNTPs), one or more of which may be labeled to facilitate detection. The reaction mixture is subjected to several rounds of thermocycling to produce multiple copies (amplification products) of the target nucleotide sequence. Amplification products are then detected  
20 in the sample, for example by detecting radioactively labeled amplification products.

Hybridization probes and PCR primers may also be selected from the genomic sequences corresponding to the full-length proteins identified in accordance with the present invention, including promoter, enhancer elements and introns of the gene encoding the naturally occurring polypeptide.

25 Nucleotide sequences encoding a prostate tumor antigen polypeptide can also be used to construct hybridization probes for mapping the gene which encodes that prostate tumor antigen and for the genetic analysis of individuals. The nucleotide sequences provided herein may be mapped to a chromosome and specific regions of a chromosome using known techniques, such as *in situ* hybridization, linkage analysis against known chromosomal markers, and hybridization screening with libraries. Briefly, sequences can be mapped to chromosomes by preparing PCR primers (preferably  
30 15-25 bp) from the prostate tumor antigen cDNA. Computer analysis of the 3' untranslated region is used to rapidly select primers that do not span more than one exon in the genomic DNA, which would complicate the amplification process. These primers are then used for PCR screening of somatic cell hybrids containing individual human chromosomes. Only those hybrids containing the human gene corresponding to the primer will yield an amplified fragment.

PCR mapping of somatic cell hybrids is a rapid procedure for assigning a particular DNA to a particular chromosome. Using the present invention with the same oligonucleotide primers, sublocalization can be achieved with panels of fragments from specific chromosomes or pools of large genomic clones in an analogous manner. Other mapping strategies that can similarly be used to map to its chromosome include *in situ* hybridization, prescreening with labeled flow-sorted chromosomes and preselection by hybridization to construct chromosome specific-cDNA libraries.

Individuals carrying variations of, or mutations in the gene encoding a prostate tumor antigen of the present invention may be detected at the DNA level by a variety of techniques. Nucleic acids used for diagnosis may be obtained from a patient's cells, including, for example, tissue biopsy and autopsy material. Genomic DNA may be used directly for detection or may be amplified enzymatically by using PCR [Saiki, *et al.*, *Nature* 324:163-166 (1986)] prior to analysis. RNA or cDNA may also be used for the same purpose. As an example, PCR primers complementary to the nucleic acid of the present invention can be used to identify and analyze mutations in the gene of the present invention. Deletions and insertions can be detected by a change in size of the amplified product in comparison to the normal genotype.

Point mutations can be identified by hybridizing amplified DNA to radiolabeled RNA of the invention or alternatively, radiolabeled antisense DNA sequences of the invention. Sequence changes at specific locations may also be revealed by nuclease protection assays, such as RNase and S1 protection or the chemical cleavage method [*e.g.* Cotton, *et al.*, *Proc. Natl. Acad. Sci. USA* 85:4397-4401 (1988)], or by differences in melting temperatures. "Molecular beacons" [Kostrikis, *et al.*, *Science* 279:1228-1229 (1998)], hairpin-shaped, single-stranded synthetic oligonucleotides containing probe sequences which are complementary to the nucleic acid of the present invention, may also be used to detect point mutations or other sequence changes as well as monitor expression levels of prostate tumor antigens.

Polynucleotides which encode a prostate tumor antigen, or complements of such polynucleotides, may also be used for therapeutic purposes. Expression of a prostate tumor antigen may be modulated through antisense technology, which controls gene expression through complementary polynucleotides, *i.e.* antisense DNA or RNA, to the control, 5' or regulatory regions of the gene encoding the prostate tumor antigen. For example, the 5' coding portion of the polynucleotide sequence which codes for the protein of the present invention is used to design an antisense oligonucleotide of from about 10 to 40 base pairs in length. Oligonucleotides derived from the transcription start site, *e.g.* between positions -10 and +10 from the start site, are preferred. An antisense DNA oligonucleotide is designed to be complementary to a region of the gene involved in transcription [Lee, *et al.*, *Nucl. Acids Res.* 6:3073 (1979); Cooney, *et al.*, *Science* 241:456 (1988); and Dervan, *et al.* *Science* 251:1360 (1991)], thereby interfering with or preventing transcription and

the subsequent production of the prostate tumor antigen. An antisense RNA oligonucleotide hybridizes to the mRNA *in vivo* and blocks translation of the mRNA molecule into the prostate tumor antigen protein [Okano, *J. Neurochem.* 56:560 (1991)]. The antisense constructs can be delivered to cells by procedures known in the art such that the antisense RNA or DNA may be expressed *in vivo*.

5       The therapeutic polynucleotides of the present invention may be employed in combination with a suitable pharmaceutical carrier. Such compositions comprise a therapeutically effective amount of the compound, and a pharmaceutically acceptable carrier or excipient. Such a carrier includes but is not limited to saline, buffered saline, dextrose, water, glycerol, ethanol, and combinations thereof. The formulation is selected according to the mode of administration.

10       Prostate tumor antigen polypeptides, as well as agonist or antagonist polypeptides which modulate the biological activity thereof, may be employed in accordance with the present invention by expression of such polypeptides *in vivo* (*i.e.* "gene therapy"). Cells from a patient may be engineered to incorporate a polynucleotide (DNA or RNA) encoding such a polypeptide *ex vivo*, with the engineered cells then administered to a patient. Such treatment methods are known in the art. For  
15 ~~example, cells may be engineered by use of a retroviral particle containing RNA encoding a~~  
polypeptide of the present invention.

Alternatively, cells may be engineered *in vivo* for expression of a polypeptide *in vivo* by procedures known in the art. By way of example, a producer cell capable of producing a retroviral particle containing RNA encoding a polypeptide of the present invention may be administered to a  
20 patient for engineering of cells and expression, with both steps taking place *in vivo*. The expression vehicle for engineering cells may be other than a retrovirus, for example, an adenovirus which may be used to engineer cells *in vitro* or *in vivo* for subsequent *in vivo* administration in a suitable delivery vehicle [see, for example, Griscelli, *et al.*, *Proc. Nat. Acad. Sci.* 95:6367-6372 (1998)].

Nucleic acids which encode a prostate tumor antigen polypeptide or any of its modified forms  
25 can also be used to generate either transgenic animals or "knock out" animals which, in turn, are useful in the development and screening of therapeutically useful reagents. A transgenic animal, such as a mouse or rat is an animal having cells that contain a transgene, which transgene was introduced into the animal or an ancestor of the animal at a prenatal, *e.g.*, an embryonic stage. A transgene is DNA which is integrated into the genome of a cell from which the transgenic animal develops. A  
30 cDNA encoding prostate tumor antigen can be incorporated into genomic DNA in accordance with established techniques, with the genomic DNA used to generate transgenic animals that contain cells which express the prostate tumor antigen. Methods for generating transgenic animals, particularly animals such as mice and rats, have become conventional in the art and are described, for example, in U.S. Patent Nos. 4,736,866 and 4,870,009. Such transgenic animals can be used to examine the  
35 effect of modified expression of DNA encoding a particular prostate tumor antigen. Such animals can

be used as tester animals for reagents thought to confer protection from, for example, pathological conditions associated with the expression or overexpression of a particular prostate tumor antigen. Accordingly, an animal is treated with the reagent and a reduced incidence of a pathological condition associated with a particular prostate tumor antigen, compared to untreated animals bearing the transgene, would indicate a potential therapeutic intervention for the pathological condition.

Alternatively, non-human homologues of a prostate tumor antigen can be used to construct a "knock out" animal which has a defective or altered gene encoding a selected prostate tumor antigen. For example, cDNA encoding the prostate tumor antigen can be used to clone genomic DNA encoding a prostate tumor antigen in accordance with established techniques. A portion of the genomic DNA encoding the prostate tumor antigen can be deleted or replaced with another gene, such as a gene encoding a selectable marker which can be used to monitor integration. Typically, several kilobases of unaltered flanking DNA (both at the 5' and 3' ends) are included in the vector [see for example, Thomas and Capecchi, *Cell* 51:503 (1987)]. The vector is introduced into an embryonic stem cell line and cells in which the introduced DNA has homologously recombined with the endogenous DNA are selected [see *e.g.*, Li, *et al.*, *Cell* 69:915 (1992)]. The selected cells are then injected into a blastocyst of an animal (*e.g.*, a mouse or rat) to form aggregation chimeras [see *e.g.*, Bradley, in TERATOCARCINOMAS AND EMBRYONIC STEM CELLS: A PRACTICAL APPROACH, E.J. Robertson, Ed. (IRL, Oxford), 113-152 (1987)]. A chimeric embryo can then be implanted into a suitable female foster animal and the embryo brought to term to create a "knock out" animal. Progeny harboring the homologously recombined DNA in their germ cells can be identified by standard techniques. Knockout animals can be characterized for instance, for the absence of a pathological condition normally associated with a selected prostate tumor antigen.

#### B. Polypeptides

Similarly, knowledge of the full-length, and in some cases the partial nucleotide sequences provided herein, provides the basis for identifying the various polypeptides encoded by the nucleotides described herein. Such polypeptide antigens, or immunogenic fragments thereof, can be used, for example, to elicit an immune response (humoral or cellular) in a host organism for the purpose of eradicating tumor cells present in the organism, or to stimulate production of polyclonal and/or monoclonal antibodies for therapy or for use in diagnostic kits in accordance with the present invention. The polypeptides of the present invention have numerous uses including, but not limited to, utility in producing vaccines against tumor-specific antigens. Such vaccines may be formulated to produce a humoral (antibody) or cellular immune response in the target organism. Generally, vaccine compositions may be produced using full-length polypeptides or antigenic peptides, where the latter are generally conjugated to an immunogenic carrier and cellular immune stimulatory

compositions may be produced according to methods such as described in co-owned, co-pending U.S. Application No. 08/579,823, incorporated herein by reference.

Polypeptides in accordance with the present invention may also find utility in detection methods, such as in radioimmunoassay- and ELISA-based diagnostic assays. Such polypeptides may  
5 also be used to produce antibodies to be used as reagents in such assays. The set up and optimization of such assays is within the skill of those practiced in the art of assay development.

The present invention also includes a method for identifying a receptor for a prostate tumor antigen. The gene encoding a prostate tumor antigen-receptor can be identified by numerous methods known to those of skill in the art, for example, ligand panning and FACS sorting [Coligan, *et al.*,  
10 *Current Protocols in Immunol.* 1(2), Chapter 5 (1991)]. Preferably, expression cloning is employed wherein polyadenylated RNA is prepared from a cell responsive to prostate tumor antigen, and a cDNA library created from this RNA is divided into pools and used to transfect COS cells or other cells that are not responsive to prostate tumor antigen. Transfected cells which are grown on glass slides are exposed to labeled prostate tumor antigen. The prostate tumor antigen can be labeled by  
15 a variety of means including iodination or inclusion of a recognition site for a site-specific protein kinase. Following fixation and incubation, the slides are subjected to autoradiographic analysis. Positive pools are identified and sub-pools are prepared and retransfected using an iterative sub-pooling and rescreening process, eventually yielding a single clone that encodes the putative receptor.

As an alternative approach for receptor identification, labeled prostate tumor antigen can be  
20 photoaffinity linked with cell membrane or extract preparations that express a receptor molecule. Cross-linked material is resolved by PAGE and exposed to X-ray film. A labeled complex containing the prostate tumor antigen-receptor can be excised, resolved into peptide fragments, and subjected to protein microsequencing. The amino acid sequence obtained from microsequencing can be used to design a set of degenerate oligonucleotide probes to screen a cDNA library to identify the gene  
25 encoding a putative receptor.

The present invention also includes methods for identifying molecules, such as synthetic drugs, antibodies, peptides, or other molecules, which have a modulating effect on the activity of the prostate tumor antigen *e.g.* agonists or antagonists of the prostate tumor antigen-receptor.

When a prostate tumor antigen binds to another protein, for example, when the prostate tumor  
30 antigen functions as a receptor, the prostate tumor antigen can be used in assays to identify other proteins or molecules which may participate in the binding interaction. By such methods, inhibitors of the receptor/ligand binding interaction can be identified. Proteins involved in such binding interactions can also be used to screen for peptide or small molecule inhibitors or agonists of the binding interaction.

Screening assays can be designed to find compounds that modulate the biological activity of a native prostate tumor antigen or a receptor for such a prostate tumor antigen. Preferred screening assays will be amenable to high-throughput screening of chemical libraries, making them particularly suitable for identifying small molecule drug candidates. Small molecules contemplated include synthetic organic or inorganic compounds. The assays can be performed in a variety of formats, including protein-protein binding assays, biochemical screening assays, immunoassays and cell based assays, all of which are well characterized in the art.

### C. Antibodies

A prostate tumor antigen polypeptide may also be used to generate antibodies, however, the prostate tumor antigen polypeptide must share at least one epitope or determinant with the full length protein sequence shown in any one of Figures 9A-C or 11. By "epitope" or "determinant" herein is meant a portion of a protein which will generate and/or bind an antibody. Thus, in most instances, antibodies made to a smaller prostate tumor antigen polypeptide will be able to bind to the full length protein. It is preferred that the epitope be unique; that is, antibodies generated to the unique epitope show little or no cross-reactivity with other antigens. In other words, the antibodies of the invention specifically bind to prostate tumor antigens. By "specifically bind" herein is meant that the antibodies bind to the protein with a binding constant in the range of at least  $10^6$ - $10^8$  M, with a preferred range being  $10^7$ - $10^9$  M.

The anti-prostate tumor antigen antibodies of the present invention have various utilities, *e.g.*, they may be used in diagnostic assays for the presence of prostate tumor antigen, such as detecting expression in specific cells, tissues, and/or serum. Various diagnostic assays known in the art may be used, such as competitive binding assays, direct or indirect sandwich assays and immunoprecipitation assays conducted in either heterogeneous or homogeneous phases [Zola, MONOCLONAL ANTIBODIES: A MANUAL OF TECHNIQUES, CRC Press, Inc., 147-158 (1987)]. The antibodies used in such diagnostic assays can be labeled with a detectable label. The detectable label should be capable of producing, either directly or indirectly, a detectable signal. For example, the detectable label may be a radioisotope, such as  $^3\text{H}$ ,  $^{14}\text{C}$ ,  $^{32}\text{P}$ ,  $^{35}\text{S}$ , or  $^{125}\text{I}$ , a fluorescent or chemiluminescent compound, such as fluorescein isothiocyanate (FITC), rhodamine, or luciferin, or an enzyme, such as alkaline phosphatase, beta-galactosidase or horseradish peroxidase. Any method known in the art for conjugating the antibody to the detectable label may be employed, including those methods described by Hunter, *et al.*, *Nature* 144:945 (1962); David, *et al.*, *Biochemistry* 13:1014 (1974); Pain, *et al.*, *J. Immunol. Meth.* 40:219 (1981); and Nygren, *J. Histochem. and Cytochem.* 30:407 (1982).



Anti-prostate tumor antigen antibodies are useful for the affinity purification of prostate tumor antigens from recombinant cell culture or natural sources. In this process, the antibodies against a prostate tumor antigen are immobilized on a suitable support, such a Sephadex resin or filter paper, using methods well known in the art. The immobilized antibody is then contacted with a sample  
5 containing the prostate tumor antigen to be purified, and thereafter the support is washed with a suitable solvent that will remove substantially all the material in the sample except the prostate tumor antigen, which is bound to the immobilized antibody. Finally, the support is washed with another suitable solvent that will release the prostate tumor antigen from the antibody.

The prostate tumor antibodies of the present invention are capable of reducing or eliminating  
10 the biological function of the prostate tumor antigen with which they specifically react. That is, the addition of either polyclonal or preferably monoclonal anti-prostate tumor antigen antibodies to cells comprising prostate tumor receptors may reduce or eliminate the pathology associated with the presence of a prostate tumor. Generally, at least a 50% decrease in activity is preferred, with at least about 75% being more preferred at least about 85-90% being particularly preferred and about a 95-  
15 100% decrease being especially preferred.

Anti-prostate tumor antibody compositions are tested in appropriate *in vitro* and *in vivo* animal models of disease, to confirm specificity, efficacy, tissue metabolism, and to estimate dosages, according to methods known in the art.

Anti-prostate tumor antibody compositions may be administered by any of a number of routes  
20 and methods designed to provide a consistent and predictable concentration of antibody at the target tissue. The antibody compositions may be administered alone, or in combination with other agents, such as stabilizing compounds, and/or in combination with other pharmaceutical agents such as drugs or hormones. Therapeutic value may be achieved by administering one or more antibodies specific for a prostate tumor antigen. Such antibodies may be useful in preventing the interaction of a tumor  
25 antigen with its receptor.

A human or humanized monoclonal antibody is preferred in the therapeutic application of the present invention. The antibody is typically administered as a sterile solution by IV injection in an amount between about 1-15 mg/kg body weight of the subject, although other parenteral routes of administration may be suitable. Appropriate treatment regimens will vary depending upon the affinity  
30 of the particular antibody selected, the route of administration selected, the dose and patient condition. These parameters are easily determinable by the skilled practitioner using routine experimentation. In one exemplary method, the antibody treatment is used to inhibit tumor growth, by administering the antibody to the site of the tumor, and such administration is continued until a therapeutic improvement is seen.

A therapeutic composition for use in the treatment method can include the antibody in a sterile injectable solution, the antibody in an oral delivery vehicle, or the polypeptide in a nebulized form, all prepared according to well known methods. Such compositions comprise a therapeutically effective amount of the antibody, and a pharmaceutically acceptable carrier or excipient. Such a carrier includes but is not limited to saline, buffered saline, dextrose, water, glycerol, ethanol, and combinations thereof.

The following examples are offered for illustrative purposes only, and are not intended to limit the scope of the present invention in any way.

All patent and literature references cited in the present specification are hereby incorporated by reference in their entirety.

#### IV. Materials and Methods

##### A. Differential Display Detection Kit and Primers

A commercial differential display detection kit, "HIEROGLYPH mRNA Profile System" (GENOMYX Corp., Foster City, CA) was used to identify polynucleotides that are specific to prostate tumor cells. This system is designed to produce cDNA fragments of up to 1.2-1.5 kb in length with excellent reproducibility between duplicate samples. The HIEROGLYPH anchored primers incorporate a 17 nt T7 NA polymerase promoter-derived site (ACGACTCACTATAGGGC; SEQ ID NO:12) to allow directional sequencing from the 3' end of the original mRNA transcript without requiring fragment/vector subcloning. The core annealing sequences of the arbitrary 5' primers used in the HIEROGLYPH system are 10 bases in length. Twenty different arbitrary upstream primers are used. Arbitrary Primers (ARPs) incorporate a 16-nt segment of the M13 universal reverse (148) 24 mer primer sequence, ACAATTTTCACACAGCA, (SEQ ID NO:13) which allows directional sequencing from the 5'-end of the original transcript. Each ARP is therefore 26 nt in length.

##### B. Enrichment of Subtracted Prostate cDNA

"Highly enriched" subtracted prostate cDNA was prepared by methods detailed in the cDNA Subtraction Kit from Clontech Laboratories (Palo Alto, CA). Briefly, tester cDNA was prepared from normal human prostate poly A+ RNA; the cDNA population that contains the tissue-specific sequences of interest. Driver cDNA was prepared from a mixture of poly A+ RNA prepared from 10 different tissues including spleen, thymus, brain, heart, kidney, liver, lung, ovary, placenta, and skeletal muscle. Subtractive hybridization and primary PCR were performed using these two populations.

### C. Cloning of Prostate Tumor Specific Nucleic Acids

All cloning procedures were carried out with commercially available kits according to protocols provided by the manufacturer. The subtracted prostate DNA was generated with the "Clontech PCR-select cDNA subtraction kit" (Clontech, Palo Alto, CA). Subcloning procedures were carried out with the "TA cloning kit" (Invitrogen, Carlsbad, CA).

#### Example 1

#### Molecular Cloning of Genes from Prostate Tumor Cells

The mRNA expression patterns of normal prostate, the prostatic carcinoma cell line LNCaP (ATCC CRL 1740; American Type Culture Collection; Rockville, MD) and of HeLa cells were compared by differential display (DD) using the HIEROGLYPH mRNA Profile System described above. All procedures were carried out essentially as described in the manufacturer's instructions provided as a package insert and incorporated herein by reference. Briefly, DNA-free total RNA was isolated from cell lines using the SNAP Total RNA kit (Invitrogen, San Diego, CA). RNA from prostatic tissue was commercially obtained from Clontech, Inc. (Palo Alto, CA) and was treated from RNase free DNase to remove genomic DNA contaminants. Qualitatively, the RNA had a minimum OD260/OD280 ratio of greater than 1.8. The RNA was determined to be intact by electrophoretic analysis.

First strand cDNA copies of the RNA transcripts were generated using commercially available transcriptase ("SUPERScript", Life Technologies, Rockville, MD) and 3' "anchored" primers provided in the HIEROGLYPH kit. The reaction was carried out at 42°C for one hour. The reverse transcribed RNA was then subjected to amplification by polymerase chain reaction (PCR) using duplicate reactions having pairwise combinations of ten anchored 3' and four arbitrary 5' primers. The anchored primers were identical to those used in the reverse transcriptase reaction. Also present in the reaction mixtures were AMPLITAQ DNA polymerase and [ $\alpha$ -<sup>32</sup>P]dATP. Four PCR cycles were run at 46°, and 25 cycles were run at 60°. Reaction products were separated by electrophoresis on a 4.5% and/or a 6% HR-1000 gel followed by autoradiography of the resulting gels.

Twenty primer combinations were evaluated in duplicate experiments from each of the three mRNA sources, for a total of 120 PCR reactions. The DD-PCR fragments generated from the screening regimen were analyzed by gel electrophoresis on 33 (61 cm gels using the genomyxLR and HR-1000 gels). Autoradiographs of the gels were analyzed for bands that are specifically expressed only in the prostatic carcinoma cell line sample LNCaP but not in the HeLa carcinoma or in normal prostate. A total of 54 DD products were identified that met these criteria; the bands excised from the gels and reamplified by PCR. The PCR products were purified via agarose gel electrophoresis,

and 5' ends were subjected to DNA sequencing by cycle sequencing with dideoxy terminators. The sequence was obtained for all 54 fragments. The 54 fragments revealed 35 different mRNA transcripts, which were compared to daily updated database releases of GenBank, GenBank EST division and EMBL. A total of eight mRNAs/CDNAs were found to be novel, as evidenced by lack of significant database match with BLASTN or TBLASTX algorithms (Example 2, SEQ ID NO:1-4, 6-8). SEQ ID NO:5 was identified as a novel member of the thioredoxin reductase gene family by this method.

### Example 2

10

#### Screening of Selected Nucleotide Sequences

##### A. Sequence Identity Screening of SEQ ID 1-8

15

Nucleotide sequences were screened with the BLASTN and TBLASTX algorithm against the NCBI Entrez NR (May 6, 1997; 309920 sequences) and NCBI Entrez EST (May 6, 1997; 10155474 sequences) database releases. SEQ ID NOs:1-4 and 6-8 were found to have no significant sequence similarity with any known sequences. SEQ ID NO:5 was found to have substantial homology (approximately 78%) by BLASTN to an uncharacterized mouse EST. Amino acid sequences deduced from SEQ ID NO:5, incorporated herein as SEQ ID NOs:9-11, were also determined to have homology by TBLASTX with portions of mouse and human thioredoxin reductase, suggesting that the detected nucleotide sequence encodes a novel member of the thioredoxin reductase gene family.

20

##### B. Sequence Identity Screening of SP 1-4 Sequences

25

The SP 1-4 nucleotide sequence (SEQ ID NO:14) was screened with the BLASTN and TBLASTX algorithms against the NCBI Entrez NR and NCBI Entrez EST database releases (July 1, 1998). SEQ ID NO:14 and partial sequences thereof were found to have less than about 45% sequence identity to any known nucleic acid sequence. The deduced SP 1-4 amino acid sequence, SEQ ID NO:15, was found to have less than about 30% sequence identity to any known polypeptides over the entire length of the sequence using the BLASTP algorithm in a search comparing amino acids 1 to 1095 of SEQ ID NO:15 to the "non-redundant Genbank CDS translations+PDB+SwissProt+Spupdate+PIR" database on July 1, 1998, suggesting that the SP 1-4 nucleotide sequence encodes a novel protein.

30

Example 3Molecular Cloning of Human SP 1-4 cDNAA. Isolation of Original Partial cDNA Insert

Human subtracted prostate cDNA, highly enriched for prostate specific partial cDNA sequences, was amplified using the primer pair as follows:

NP1 5'-TCGAGCGGCCGCCCCGGGCAGGT-3' (SEQ ID NO:16)

NP2 5'-AGGGCGTGGTGCGGAGGGCGGT-3' (SEQ ID NO:17)

on a Perkin-Elmer GeneAmp 9600 Cycler for 11 cycles with the following thermal cycling profile: 94°C for 10 sec; 68°C for 30 sec; 72°C for 5 min. This was followed by one additional round at 72°C for 5 min. The products were ligated into the pCR2.1 TA cloning vector (Invitrogen, San Diego, CA) and transformed into *E. coli*. Individual ampicillin resistant bacterial transformants were screened by PCR for the presence of an insert using the primer pair as follows:

M13 Reverse 5'-CAGGAAACAGCTATGA-3' (SEQ ID NO:18)

M13 Forward 5'-GTAAAACGACGGCCAGTG-3' (SEQ ID NO:19)

and the following thermal cycling profile: 94°C for 15 sec; 55°C for 30 sec; 72°C for 1 min. This was followed by one additional round at 72°C for 6 min. The original SP 1-4 insert in the pCR2.1 plasmid (SEQ ID NO:29) was sequenced using the M13 reverse primer (SEQ ID NO:18), and the M13-20 primer (SEQ ID NO:19), on an ABI 373 DNA Sequencer. The original SP 1-4 insert (SEQ ID NO:29) corresponds to the nucleotides 1534-1875 of SEQ ID NO:14. DNA sequences were analyzed using Sequencher 3.0 (Gene Codes Corporation, Ann Arbor, MI).

B. Isolation of Full Length SP 1-4 cDNA

Marathon cDNA from normal human prostate poly A<sup>+</sup> RNA was prepared for carrying out both 5' and 3' Rapid Amplification of cDNA Ends [RACE, Frohman, *et al.*, *Proc. Nat. Acad. Sci.* 85:8998-9002, (1988), Clontech Laboratories, Palo Alto, CA]. 5' RACE was carried out with the following primer pair:

AP1 5'-CCATCCTAATACGACTCACTATAGGGC-3' (SEQ ID NO:20)

A79331 5'-GCCGAGTAATAGGAGACACGTCGTGG-3' (SEQ ID NO:21)

3' RACE was carried out with the following primer pair:

AP1	5'-CCATCCTAATACGACTCACTATAGGGC-3'	(SEQ ID NO:20); and
A79326	5-TGGAAACTGGTTGCGAACTTCCG-3'	(SEQ ID NO:22)

5

The thermal cycling profile for all RACE reactions was 94°C for 15 sec; 68°C for 4 min for 30 cycles using Advantage cDNA Polymerase Mix (Clontech Laboratories, Palo Alto, CA). 5' and 3' RACE products of approximately 4 kb and 1.6 kb respectively were isolated by agarose gel electrophoresis, ligated into the pCR2.1 TA vector (Invitrogen, San Diego, CA), and transformed into competent *E. coli* cells. Individual ampicillin resistant bacterial colonies were screened by PCR for the presence of an insert with the following primer pair:

AP2	5'-ACTCACTATAGGGCTCGAGCGGC-3'	(SEQ ID NO:23)
A79331	5'-GCCGAGTAATAGGAGACACGTCGTGG-3'	(SEQ ID NO:21)

15

for the 5' RACE products and the following primer pair:

AP2	5'-ACTCACTATAGGGCTCGAGCGGC-3'	(SEQ ID NO:23)
A79328	5'-CAAAGTCATTTGGCAGCAGACCAGG-3'	(SEQ ID NO:24)

20

for the 3' RACE products using a thermal cycling profile of 94°C for 15 sec; 55°C for 30 sec; 72°C for 1 min for 35 cycles, followed by one additional round at 72°C for 6 min. PCR products were resolved by agarose gel electrophoresis, and individual bacterial transformants were grown in liquid culture (Luria-Broth supplemented with ampicillin 100 µg/ml) prior to preparation of plasmid DNA.

25 The complete DNA sequence of individual RACE products was determined by automated fluorescent sequencing using an ABI 373 DNA sequencer in conjunction with custom DNA primers and the Primer Island Transposition Kit (Perkin-Elmer/Applied Biosystems Division, Foster City, CA).

The entire 5668 base pair nucleotide sequence designated SP 1-4 cDNA, is shown in Figure 10 (SEQ ID NO:14). The sequence contains a single open reading frame with an apparent translational initiation site at nucleotide positions 43-45 [Kozak, *et al.*, *Nucl. Acids Res.* 12:3873-3893 (1984)] with a stop codon at nucleotide positions 3328-3330 (Figure 10).

30 The full-length SP 1-4 protein, (SEQ ID NO:15), shown in Figure 11 is 1095 amino acids long. Important regions of the amino acid sequence of the SP 1-4 protein include the transmembrane regions corresponding to amino acids 732-748, 846-876, 681-703, 789-805, 944-971, 820-837, and 35 999-1015, respectively, and potential N-glycosylation sites, beginning at amino acids 6, 75, 247, 308,

812, 925, 1041, and 1063, respectively. Clones pCR2.1/SP 1-4 (5' RACE, SEQ ID NO:27) and pCR2.1/SP 1-4 (3' RACE, SEQ ID NO:28) have been deposited with ATCC and are assigned ATCC deposit numbers 98829 and 98829, respectively.

5

#### Example 4

#### Expression of Human SP 1-4

##### A. RT-PCR

First strand cDNA synthesis was prepared using human poly A+ RNA's and the SMART PCR cDNA Synthesis Kit (Clontech Laboratories, Palo Alto, CA). The primer pair

10

A80552      5'-GATTTTCACCAATGACCGCCG-3'      (SEQ ID NO:25);  
and A80553      5'-CCCCAGCAGCATTGATGTCTG-3'      (SEQ ID NO:26)

15

was used to assess expression with a thermal cycling profile of 94°C for 15 sec; 65°C for 15 sec; 72°C for 30 sec (30 cycles), followed by one additional round at 72°C for 6 min. Amplification products were resolved by agarose gel electrophoresis and visualized by ethidium bromide staining and ultraviolet light.

20

As shown in Table 1 below, numerous samples were amplified and SP 1-4-specific mRNA expression clearly detected by RT-PCR in testis and prostate tissue, as well as in a colorectal adenocarcinoma cell line, (SW480), a melanoma tissue sample (G361) and in LNCaP which is a prostatic carcinoma cell line.

**Table 1**

Sample	PCR Product
Spleen	neg
Mammary Gland	trace
Placenta	neg
Kidney	neg
Liver	neg
Lung	neg
Testis	+
SW480 (colorectal adenocarcinoma)	+
G361 (melanoma)	+
LNCaP	+
Prostate	++
PC3	neg
DU145	neg
Skeletal Muscle	neg
Bone Marrow	neg
Brain	neg
Heart	neg
A549 (lung carcinoma)	neg
Pancreas	neg
Intestine	neg
Thymus	trace

#### B. Nucleic Acid Hybridization

The original insert isolated from the subtracted library was used as a hybridization probe for Northern blot and RNA dot blot analysis. The fragment was random primer labeled with  $^{32}\text{P}$ -dCTP, purified on a G-50 micro-spin column, and hybridized to filters using ExpressHyb Hybridization Solution (Clontech Laboratories, Palo Alto, CA) at 68°C for 2-4 hours. The filters were washed sequentially in 2X SSC [1X SSC = 150 mM NaCl, 15 mM sodium citrate], 0.1% SDS at room temperature for 30 min, 0.5X SSC, 0.1% SDS at room temperature for 30 min, and 0.5X, 0.1% SDS at 65°C for 30 min. Autoradiography was performed for one hour to one day at -70°C using Kodak XAR film and a single intensifying screen.



The results of human RNA dot blot and Northern blot analysis of numerous tissues, both adult and fetal in origin as shown in Tables 2 and 3 below, respectively, indicate that SP 1-4- specific mRNA is preferentially expressed in prostate tissue.

5

**Table 2**

10

15

20

25

30

Sample	SP 1-4 Signal	Sample	SP 1-4 Signal
whole brain	neg	salivary gland	neg
amygdala	neg	mammary gland	neg
caudate nucleus	neg	kidney	trace
cerebellum	neg	liver	neg
cerebral cortex	neg	small intestine	neg
frontal lobe	neg	spleen	neg
hippocampus	neg	thymus	neg
medulla oblongata	neg	peripheral leukocyte	neg
occipital lobe	neg	lymph node	neg
putamen	neg	bone marrow	neg
substantia nigra	neg	appendix	neg
temporal lobe	neg	lung	neg
thalamus	neg	trachea	neg
subthalamic nucleus	neg	placenta	neg
spinal cord	neg	fetal brain	neg
heart	neg	fetal heart	neg
aorta	neg	fetal kidney	neg
skeletal muscle	neg	fetal liver	neg
colon	neg	fetal spleen	neg
bladder	neg	fetal thymus	neg
uterus	neg	fetal lung	neg
prostate	++++	pancreas	neg
stomach	neg	pituitary gland	neg
testis	trace	adrenal gland	neg
ovary	neg	thyroid gland	neg

**Table 3**

Sample	SP 1-4 Transcripts
HL-60	neg
HeLA	neg
K562	neg
Molt-4	neg
Burkitts Lymphoma	neg
colorectal adenocarcinoma SW480	neg
lung carcinoma A549	neg
Melanoma G361	+
skeletal muscle	neg
uterus	neg
colon	neg
small intestine	neg
bladder	neg
heart	neg
stomach	neg
prostate	+++++

While the invention has been described with reference to specific methods and embodiments, it will be appreciated that various modifications and changes may be made without departing from the invention.

---

**IT IS CLAIMED:**

---

1. An isolated polynucleotide comprising a sequence selected from the group consisting of SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8 and SEQ ID NO:14, or the complement of any of said sequences.  
5
2. The isolated polynucleotide of claim 1, wherein said polynucleotide has at least 80% sequence identity to a sequence selected from the group consisting of SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8 and SEQ ID NO:14, or the complement of any of said sequences.  
10
3. The isolated polynucleotide of claim 1, wherein said polynucleotide is an RNA molecule.
- 15 4. An isolated polynucleotide according to claim 1, wherein said polynucleotide has at least 80% sequence identity to nucleotides 43-3327 of the sequence of SEQ ID NO:14, its complement, and contiguous fragments thereof at least 30 nucleotides in length.
5. An isolated polynucleotide according to claim 1, wherein said polynucleotide  
20 hybridizes under high stringency conditions to nucleotides 43-3327 of the sequence of SEQ ID NO:14, or the complement thereof.
6. An isolated polynucleotide according to claim 1 consisting essentially of nucleotides 43-3327 of the nucleotide sequence of SEQ ID NO:14.  
25
7. An isolated polynucleotide according to claim 1 which encodes an extracellular domain of a prostate tumor antigen polypeptide.
8. A vector comprising the nucleic acid of any one of Claims 1 to 7 operably linked to  
30 control sequences recognized by a host cell transformed with said vector.
9. A host cell comprising the vector of Claim 8.
10. A process for producing a prostate tumor antigen polypeptide comprising

(a) culturing the host cell of Claim 9 under conditions suitable for expression of said prostate tumor antigen polypeptide; and

(b) recovering said prostate tumor antigen polypeptide from the cell culture.

5           11.     An isolated prostate tumor antigen peptide encoded by a polynucleotide having at least 80% sequence identity to a sequence selected from the group consisting of SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, and contiguous fragments thereof at least 10 amino acids in length, where said peptide is antigenic.

10           12.     An isolated prostate tumor antigen polypeptide encoded by a polynucleotide having at 80% sequence identity to amino acid residues 1 to 1095 of Figure 11 (SEQ ID NO:15), and contiguous fragments thereof at least 10 amino acids in length where said polypeptide is antigenic.

          13.     An isolated polynucleotide that encodes a polypeptide of claim 11 or 12.

15

          14.     An isolated prostate tumor antigen peptide encoded by a polynucleotide selected from the group consisting of SEQ ID NO:9, SEQ ID NO:10 and SEQ ID NO:11.

          15.     An isolated prostate tumor antigen polypeptide encoded by a polynucleotide  
20 comprising amino acid residues 1 to 1095 of Figure 11 (SEQ ID NO:15).

          16.     A chimeric molecule comprising a prostate tumor antigen peptide or polypeptide according to claim 14 or 15 and fused to a heterologous amino acid sequence.

25           17.     An antibody which specifically binds to the prostate tumor antigen peptide or polypeptide of claim 14 or 15.

          18.     A method for detecting the expression of a prostate tumor antigen in an individual comprising

30           (a) measuring the expression of prostate tumor antigen in a tissue from a first individual; and  
          (b) comparing said expression to the expression of said prostate tumor antigen in a tissue from a second, unaffected individual;

          wherein when the expression of said prostate tumor antigen from said first individual is greater than the expression of prostate tumor antigen in said second individual, the first individual is at risk  
35 for a prostate tumor antigen related condition.

---

19. A method of detecting tumor cells in a tissue sample, comprising

---

- (a) amplifying nucleic acids generated from said sample by polymerase chain reaction (PCR) using two primers, where said two primers are designed to selectively amplify a polynucleotide sequence according to claim 1, selected from the group consisting of SEQ ID NO:1, SEQ ID NO:2, 5 SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, and SEQ ID NO:14, or a portion of at least one of said sequences, said portion comprising at least 15 nucleotides, and
- (b) detecting the presence of amplification products that correspond to at least one of said sequences or amplified portions thereof.

1/5

CTGTATTGGAACGCCTGAAGATTTTCTATTGCTGTCAAGTACCACCTCACTGGG  
CCATTCAGCGCCAACTTGCAAGTTTGCTCTTTGAGTTGGGATGTACCAGTTCAGCC  
CTTCAGATATTTGAAAAGCTAGAAATGTGGGAAGATGTTGTCATTTGTTRTGAAAG  
AGCCGGGCAGCACGGAAAGGCAGAAGAAATCCTTAGACAAGAGCTGGAGAAAAAAG  
AAACGCCTAGTTTATACTGCTTGCTTGGAGATGTC

**Fig. 1**

AGAGGGTTAGAGGACAGGGCCTGGGCACCATCAAATAAGCTTTGGAGTTCCTGTTA  
GGGTCGGAGATCTCACTCAGTGTGACATGGGGAGCCTCTCCGGAGGCTTTGGGCAG  
AAGAGTGGTATCATCCCACTCAAGTCACGTCGGCTGCCATGTGGTGATGAGGCTAT  
TAGGTGGCTAGTGTCAAAGAAGGGAGAAGCAGCGTTATATCGGAATGGGCTCCTAC

**Fig. 2**

AAGGCAGGACTGGATTGTGRTTACRACTGAGTASTAKGCARAGAATTGGARTGTRG  
GSAACATAAAKATRATGTSAATMAAATAAGAATGGTCAATTAASACCCTAAAAAAA  
SGACRTTCAAAAATGC

**Fig. 3**

AACACACTTATAAACATTGAGTGCCATTTCCCCCCTACTTTAATAGTCTATTGCTA  
GTTCAAGGTTACTTAGCATTTCTTAGGTGACACAACATTCAAAAATGAATGTTTTT  
CCATGCATTTACTATATGCATTCCCTCTCCTGTGAATAATCTATTCATATCCATCT  
TCTGGGGACTTGAACCTCTTCTAACTTTGAACAAGCATTTTTTTTATGTTACAGATA  
TTACTTCTTTGT

**Fig. 4**

AAATTCATACCTGTGATGGTTCAACAGTTGGAGAAAGGTTACCTGGAAAGCTGAA  
AGTGTTGGCTAAATCCACTGAAGGAACAGAAACAATTGAAGGAACAGAAACAATTG  
AAGGAGTCTATAACAGTTTTGTAGCTATTGGTCGTGACTCCTGTACAAGGAAAAT  
AGGCTTGGAGGAAGATTGGTGTCAAATTAATGAGAAGAGTGGAAAAATACCTGTA

**Fig. 5**

CTCGGCAGTGAAAAGCAAGTCATTTCTGGGTCTCTCTGGAAATCAGTCCGCAGGAA  
SRCGAGKRGGRRRCRCGAGGGATGATCGTGCCTCCCCCAACCCCAGTGCAATTGTC  
TGAACAATTCAGTTCAGATTTCTACCTCTCTGGGCTCAATCCGAAGCGTTACCTC  
AGGATCTACTGAAGGAACTTTGGCCAGGTGGAAAGCAAACCATGCTCTGTCCAGAG  
ATGAAGATAAAATTGGCCATGATGA

**Fig. 6**

TGGCATGACCAGGATTCCTGTGAAAGCAGGAGCAGCAGCAATCCGTCSSGGCGCCT  
GCCTTTCCCATCCTTTGGTTCTCCTTTC

**Fig. 7**

GCTTCTGGTGGTCCTCATTCATCTTTGCATTCAGATTCAACTGGTTCATGGTTCA  
TACWGGGGGAAACAGGTCCATGGTTGGGATCCATGGGTCCCTCCAGTCTCCTGTTC  
AACGGTCGTACACACCTTGGGAGCACCCACTCGGTTTGTTCATCTTCTGCAAAGAT  
GTCATTCTACAGTCATTACCTTCCAGCCTATTTGTTTCTGCAGAATCTACATATAC  
TGTTGTATCTACCTCAAAATGCAAACACCA

**Fig. 8**

KFIPVMVQOLEKGS PGKLKVLAKSTEGTETIEG

**Fig. 9A**

TVLLAIGRDSCTRKIGLE

**Fig. 9B**

IGVKINEKSGKIPV

**Fig. 9C**

3/5

gtcacttaggaaaaggtgtcctttcgggcagccgggctcagcatgaggaa  
cagaaggaATGACACTCTGGACAGCACCCGACCCTGTACTCCAGCGCGT  
CTCGGAGCACAGACTTGTCTTACAGTGAAAAGCGACTTGGTGAATTTTATT  
CAAGCAAATTTTAAAGAAACGAGAATGTGTCTTCTTTACCAAAGATTCCAA  
GGCCACGGAGAATGTGTGCAAGTGTGGCTATGCCCAGAGCCAGCACATGG  
AAGGCACCCAGATCAACCAAAGTGAGAAATGGAAC TACAAGAAACACACC  
AAGGAATTTCTACCGACGCCTTTGGGGATATTAGTTTGAGACACTGGG  
GAAGAAAGGGAAGTATATACGTCTGTCCTGCGACACGGACGCGGAAATCC  
TTTACGAGCTGCTGACCCAGCACTGGCACCTGAAAACACCCAACCTGGTC  
ATTTCTGTGACCGGGGGCGCCAAGAACTTCGCCCTGAAGCCGCGCATGCG  
CAAGATCTTTCAGCCGGCTCATCTACATCGCGCAGTCCAAAGGTGCTTGA  
TTCTCACGGGAGGCACCCATTATGGCCTGACGAAGTACATCGGGGAGGTG  
GTGAGAGATAACACCATCAGCAGGAGTTCAGAGGAGAATATTGTGGCCAT  
TGGCATAGCAGCTTGGGGCATGGTCTCCAACCGGGACACCCTCATCAGGA  
ATTGCGATGCTGAGGGCTATTTTTTAGCCCAGTACCTTATGGATGACTTC  
ACAAGGGATCCACTGTATATCCTGGACAACAACCACACACATTTGCTGCT  
CGTGGACAATGGCTGTCATGGACATCCCACTGTCTGAAGCAAAGCTCCGGA  
ATCAGCTAGAGAAGCATATCTCTGAGCGCACTATTCAAGATTCCAAC TAT  
GGTGGCAAGATCCCCATTGTGTGTTTTGCCCAAGGAGGTGGAAGAGAGAC  
TTTGAAGCCATCAATACCTCCATCAAAAATAAAATTCCTTGTGTGGTGG  
TGGAAGGCTCGGGCCGGATCGCTGATGTGATCGCTAGCCTGGTGGAGGTG  
GAGGATGCCCCGACATCTTCTGCCGTCAAGGAGAAGCTGGTGCCTTTTT  
ACCCCGCACGGTGTCCCGGCTGTCTGAGGAGGAGACTGAGAGTTGGATCA  
AATGGCTCAAAGAAATTCTCGAATGTTCTCACCTATTAACAGTTATTAAA  
ATGGAAGAAGCTGGGGATGAAATTGTGAGCAATGCCATCTCCTACGCTCT  
ATACAAAGCCTTCAGCACCACTGAGCAAGACAAGGATAACTGGAATGGGC  
AGCTGAAGCTTCTGCTGGAGTGGAACCAAGCTGGACTTAGCCAATGATGAG  
ATTTTCACCAATGACCGCCGATGGGAGTCTGCTGACCTTCAAGAAGTCAT  
GTTTACGGCTCTCATAAAGGACAGACCCAAGTTTGTCCGCCTCTTTCTGG  
AGAATGGCTTGAACCTACGGAAGTTTCTCACCCATGATGTCCTCACTGAA  
CTCTTCTCCAACCACTTCAGCACGCTTGTGTACCGGAATCTGCAGATCGC  
CAAGAATTCTTATAATGATGCCCTCCTCACGTTTGTCTGGAACTGGTTG  
CGAACTTCCGAAGAGGCTTCCGGAAGGAAGACAGAAATGGCCGGGACGAG  
ATGGACATAGAACTCCACGACGTGTCTCCTATTACTCGGCACCCCCTGCA  
AGCTCTCTTCATCTGGGCCATTCTTTCAGAATAAGAAGGAAGCTCTCCAAAG  
TCATTTGGGAGCAGACCAGGGGCTGCACTCTGGCAGCCCTGGGAGCCAGC  
AAGCTTCTGAAGACTCTGGCCAAAGTGAAGAACGACATCAATGCTGCTGG  
GGAGTCCGAGGAGCTGGCTAATGAGTACGAGACCCGGGCTGTTGAGCTGT  
TCACTGAGTGTTACAGCAGCGATGAAGACTTGGCAGAACAGCTGCTGGTC  
TATTCCTGTGAAGCTTGGGGTGGAAGCAACTGTCTGGAGCTGGCGGTGGA  
GGCCACAGACCAGCATTTACCGCCCAGCCTGGGGTCCAGAATTTTCTTT  
CTAAGCAATGGTATGGAGAGATTTCCCGAGACACCAAGAAGCTGGAAGATT  
ATCCTGTGTCTGTTTATTATACCCTTGGTGGGCTGTGGCTTTGTATCATT  
TAGGAAGAAACCTGTGACAAGCACAAGAAGCTGCTTTGGTACTATGTGG  
CGTTCTTCACCTCCCCCTTCGTGGTCTTCTCCTGGAATGTGGTCTTCTAC  
ATCGCCTTCCTCCTGCTGTTTGCCTACGTGCTGCTCATGGATTTCCATTC  
GGTGCCACACCCCCCGAGCTGGTCTGTACTCGCTGGTCTTTGTCTCT  
TCTGTGATGAAGTGAGACAGTGGTACGTAAATGGGGTGAATTATTTACT  
GACCTGTGGAATGTGATGGACACGCTGGGGCTTTTTTACTTCATAGCAGG  
AATTGTATTTTCGGCTCCACTCTTCTAATAAAAGCTCTTTGTATTCTGGAC  
GAGTCATTTTCTGTCTGGACTACATTATTTTCACTCTAAGATTGATCCAC

Fig. 10A

SUBSTITUTE SHEET (RULE 26)



4/5

ATTTTACTGTAAGCAGAACTTAGGACCCAAGATTATAATGCTGCAGAG  
GATGCTGATCGATGTGTTCTTCTTCCTGTTCCTCTTTGCGGTGTGGATGG  
TGGCCTTTGGCGTGGCCAGGCAAGGGATCCTTAGGCAGAATGAGCAGCGC  
TGGAGGTGGATATTCGGTTCGGTCATCTACGAGCCCTACCTGGCCATGTT  
CGGCCAGGTGCCCAGTGACGTGGATGGTACCACGTATGACTTTGCCCACT  
GCACCTTCACTGGGAATGAGTCCAAGCCACTGTGTGTGGAGCTGGATGAG  
CACAACCTGCCCCGGTTCCCCGAGTGGATCACCATCCCCCTGGTGTGCAT  
CTACATGTTATCCACCAACATCCTGCTGGTCAACCTGCTGGTGCCTATGT  
TTGGCTACACGGTGGGCACCGTCCAGGAGAACAATGACCAGGTCTGGAAG  
TTCCAGAGGTACTTCTGCTGCTTACTTCTACATGGTGGTGAAGAAGTGCT  
CTTCCCCTTCATCGTCTTTCGCTTACTTCTACATGGTGGTGAAGAAGTGCT  
TCAAGTGTGTGCTCAAGGAGAAAAACATGGAGTCTTCTGTCTGCTGTTTC  
AAAAATGAAGACAATGAGACTCTGGCATGGGAGGGTGTCTATGAAGGAAAA  
CTACCTTGTCAGATCAACACAAAAGCCAACGACACCTCAGAGGAAATGA  
GGCATCGATTTAGACAACTGGATACAAAGCTTAATGATCTCAAGGGTCTT  
CTGAAAGAGATTGCTAATAAAATCAAataaaactgtatgaaactctaagt  
gagaaaaatctaattatagcaagatcatattaaggaatgctgatgaacaa  
ttttgctatcgactactaaatgagagattttcagacccctgggtacatgg  
tggatgatttttaaatacaccctagtgtgtgctgagaccttgagaataaagtgt  
gtgattgggtttcatacttgaagacggatataaaggaagaatatttccttt  
atgtgttttctccagaatggtgcctgttttctctctgtgtctcaatgcctgg  
gactggaggttgatagtttaagtgtgttcttaccgcctcctttttccttt  
aatcttattttttgatgaacacatatataggagaacatctatcctatgaat  
aagaacctggtcatgctttactcctgtattgttattttgttcattttcaa  
ttgattctctacttttcccttttttgtattatgtgactaattagttggca  
tattgttataaagtctctcaaataggccagattctaaaacatgctgcagc  
aagaggaccccgctctctctcaggaaaagtgttttcatttctcaggatgct  
tcttacctgtcagaggaggtgacaaggcagctctcttgctctcttggaactc  
accaggctcctattgaaggaaccaccccttcttaaatatgtgaaaagt  
cgcccaaaatgcaaccttgaaaggcactactgactttgttcttattggat  
actcctcttattttattatttttccattaaaaataatagctggctattata  
gaaaatttagaccatacagagatgtagaagaacataaattgtccccatt  
accttaaggtaatcactgctaacaatttctggatgggtttttcaagtctat  
tttttttctatgtatgtctcaattctctttcaaaattttacagaatgtta  
tcatactacatatatactttttatgtaagctttttcacttagtattttat  
caaatatgtttttattatattcatagccttcttaaacattatatcaataa  
ttgcataaataggcaacctctagcgattaccataatttttgctcattgaagg  
ctatctccagttgatcattgggatgagcatctttgtgcatgaatcctatt  
gctgtatttgggaaaattttccaaggtagattccaataaataatctattt  
attattaaatatataaataatcgatttattattaaaaccatttataaggct  
ttttcataaatgtatagcaaatagggaattattaacttgagcataagatat  
gagatacatgaacctgaactattaaaataaaaatattatatttaaccctag  
ttaaagaagaagtcaatatgcttattttaaataattatggatggtgggcaga  
tcacttgaggtcaggaggtcgagaccagcctggccaacatggcaaaacca  
catctctactataaaaaataaaaaaattagctgggtgtggtgggtgcactcctg  
taatcccagctactcagaaggctgaggtacaagaattgctggaacctggg  
aggcggaggttgcatgaaccaagattgcaccactgcactccagccgggg  
tgacagagtgaagactccgactgaaaataaataaataaataaataaataa  
taaataaataaataattatggatggtgaagggaatggtatagaattggaga  
gattatcttactgaacacctgtagtcccagctttctctggaagtgggtgt  
atttgagcaggatgtgcacaaggcaattgaaatgcccataattagtttct  
cagctttgaatacactataaactcagtggtgaaggaggaaattttagaa

**Fig. 10B**

5/5

ggaagctactaaaagatctaatttgaaaaactacaaaagcattaactaaa  
aaagtttattttccttttgtctgggcagtagtgaaaataactactcacia  
cattcactatgtttgcaaggaattaacacaaaataaaagatgcctttttac  
ttaaacgccaagacagaaaacttgcccaatactgagaagcaacttgcatt  
agagagggaactgttaaagtgttttcaaccagttcatctggtggatgttt  
ttgcaggttactctgagaattttgcttatgaaaaatcattattttttagtg  
tagttcacaataatgtattgaacatacttctaatacaagggtgctatgtcc  
ttgtgtatgggtactaaatgtgtcctgtgtacttttgcacaactgagaatc  
ctgcggtctgggtttaatgagtggtgtcatgaaataaataatggaggaatt  
gtcaaa  
aaaaaaaaaaaaaaaaaaaaa

**Fig. 10C**

MRNRRNDTLDSTRTRYSSASRSTDLSESDLVNFIQANFKKRECVFFTKDSKATENVCKCGYAO  
SQHMEGTQINQSEKWNYYKHTKEFPTDAFGDIQFETLGKKGKYIRLSCDTDAEILYELLTQHWHL  
KTPNLVISVTGGAKNFALKPRMRKIFSRLLYIAQSKGAWILTGGTHYGLTKYIGEVVRDNTISRS  
SEENIVAIGIAAWGMVSNRDTLIRNCDAEGYFLAQYLMDDFTRDPLYILDNNHTHLLLVDNGCHG  
HPTVEAKLRNQLEKHISERTIQDSNYGGKIPIVCFAQGGGKETLKAINTSIKNKIPCVVVEGSGR  
IADVIASLVEVEDAPTSSAVKEKLVRFLLPRTVSRLSEEETESWIKWLKEILECSHLLTVIKMEEA  
GDEIVSNAISYALYKAFSTSEQDKDNWNGQLKLLLEWNQLDLANDEIFTNDRRWESADLQEVMT  
ALIKDRPKFVRLFLENGLNLRKFLTHDVLTELF SNHFSTLVYRNQLIAKNSYNDALLTFVWKLVA  
NFRRGFRKEDRNGRDEMDELHDVSPITRHPLQALFIWAILQNKELSKVIWEQTRGCTLAALGA  
SKLLKTLAKVKNDINAAGESEELANEYETRAVELFTECYSSDEDLAEQLLVYSCEAWGGSNCLEL  
AVEATDQHFTAQPGVQNFSLSKQWYGEISRDTKNWKIILCLFIIPLVGC GFVSFRKKPVDKHKLL  
WYYVAFFTSPFVVFVSWNVVVFYIAFLLLFAYVLLMDFHSVPHPELVLYSLVFLFCDEVQRWYVN  
GVNYFTDLWNVMDTLGLFYFIAGIVFRLHSSNKSSLYSGRVIFCLDYIIFTLRLIHIFTVSRNLG  
PKIIMLQRMILIDVFFFLFLFAVWMVAFGVARQGILRQNEQRWRWIFRSVIYEPYLA MFGQVPSDV  
DGTTYDFAHCTFTGNESKPLCVELDEHNLPRFPEWITIPLVCIYMLSTNILLVNLLVAMFGYTVG  
TVQENNDQVWKFORYFLVQEYCSRLNIPFPFIVFAYFYMVKKCFKCCCKEKNMESSVCCFKNED  
NETLAWEGVMKENYLVKINTKANDTSEEMRHRFRQLDTKLNDLKGLLKEIANKIK

**Fig. 11**

## SEQUENCE LISTING

<110> Dendreon Corporation, et al.

<120> Prostate Tumor Polynucleotide and  
Antigen Compositions

<130> 7636-0015.41

<140> unassigned

<141> unassigned

<150> 60/056,110

<151> 1997-08-20

<160> 29

<170> FastSEQ for Windows Version 3.0

<210> 1

<211> 257

<212> DNA

<213> Homo sapiens

<400> 1

ctgtatttga acgcctgaag attttctatt gctgtcaagt accacctcac tgggccattc 60

agcgccaact tgcaagtttg ctctttgagt tgggatgtac cagttcagcc cttcagatat 120  
 ttgaaaagct agaaatgtgg gaagatgttg tcatttgtr tgaaagagcc gggcagcacg 180  
 gaaaggcaga agaaatcctt agacaagagc tggagaaaaa agaaacgcct agtttatact 240  
 gcttgcttg agatgtc 257

<210> 2

<211> 224

<212> DNA

<213> Homo sapiens

<400> 2

agaggggtag aggacagggc ctgggcacca tcaaataagc tttggagttc ctgtaggggt 60  
 cggagatctc actcagtgtg acatggggag cctctccgga ggctttgggc agaagagtgg 120  
 tatcatccca ctcaagtcac gtcggctgcc atgtggtgat gaggctatta ggtggctagt 180  
 gtcaaagaag ggagaagcag cgttatatcg gaatgggctc ctac 224

<210> 3

<211> 128

<212> DNA

<213> Homo sapiens

<400> 3

aaggcaggac tggattgtgr ttacractga gtastakgca ragaattgga rtgtrggsaa 60  
 cataaakatr atgtsaatma aataagaatg gtcaattaas accctaaaaa aasgacrttc 120  
 aaaaatgc 128

<210> 4

---

<211> 236

<212> DNA

<213> Homo sapiens

<400> 4

aacacactta taaacattga gtgccatttc cccctactt taatagtcta ttgctagttc 60  
aagggttactt agcatttctt aggtgacaca acattcaaaa atgaatgttt ttccatgcat 120  
ttactatatg cattcctctt cctgtgaata atctattcat atccatcttc tggggacttg 180  
aacctcttct aactttgaac aagcattttt ttatgttaca gatattactt ctttgt 236

<210> 5

<211> 224

---

<212> DNA

<213> Homo sapiens

<400> 5

aaattcatat ctgtgatggt tcaacagttg gagaaagggt cacctggaaa gctgaaagtg 60  
ttggctaaat ccactgaagg aacagaaaca attgaaggaa cagaaacaat tgaaggagtc 120  
tataacagtt ttgttagcta ttggtcgtga ctctgttaca aggaaaatag gcttggagga 180  
agattggtgt caaaattaat gagaagagtg gaaaaatacc tgta 224

<210> 6

<211> 249

<212> DNA

<213> Homo sapiens

<400> 6

ctcggcagtg aaaagcaagt catttctggg tctctctgga aatcagtcg caggaasrcg 60  
 agkrgrrrcr ccgagggatg atcgtgcctc ccccaacccc agtgcaattg tctgaacaat 120  
 tcagttcaga ttctctacct ctctgggctc aatccgaagc gttacctcag gatctactga 180  
 aggaactttt gccaggtgga aagcaaacca tgctctgtcc agagatgaag ataaaattgg 240  
 ccatgatga 249

<210> 7

<211> 84

<212> DNA

<213> Homo sapiens

<400> 7

tggcatgacc aggattcctg tgaaagcagg agcagcagca atccgtcssg gcgcctgcct 60  
 ttcccatcct ttggttctcc tttc 84

<210> 8

<211> 254

<212> DNA

<213> Homo sapiens

<400> 8

gcttctggtg gtcttcattc catctttgca ttcagattca actggttcat gggtcatacw 60  
 gggggaaaca ggtccatggt tgggatccat gggtccctcc agtctcctgt tcaacggtcg 120  
 tacacacctt gggagcacc actcggtttg ttcattcttct gcaaagatgt cattctacag 180  
 tcattacctt ccagcctatt tgtttctgca gaatctacat atactgttgt atctacctca 240  
 aaatgcaaac acca 254

---

<210> 9

<211> 33

<212> PRT

<213> Homo sapiens

<400> 9

Lys Phe Ile Pro Val Met Val Gln Gln Leu Glu Lys Gly Ser Pro Gly

1

5

10

15

Lys Leu Lys Val Leu Ala Lys Ser Thr Glu Gly Thr Glu Thr Ile Glu

20

25

30

Gly

---

<210> 10

<211> 18

<212> PRT

<213> Homo sapiens

<400> 10

Thr Val Leu Leu Ala Ile Gly Arg Asp Ser Cys Thr Arg Lys Ile Gly

1

5

10

15

Leu Glu

<210> 11

<211> 14

<212> PRT

<213> Homo sapiens

<400> 11

Ile Gly Val Lys Ile Asn Glu Lys Ser Gly Lys Ile Pro Val

1

5

10

<210> 12

<211> 17

<212> DNA

<213> Artificial Sequence

<220>

<221> primer\_bind

<222> (1) ... (17)

<223> oligonucleotide primer

<400> 12

acgactcact atagggc

17

<210> 13

<211> 16

<212> DNA

<213> Artificial Sequence

<220>

<221> primer\_bind

<222> (1) ... (16)



&lt;223&gt; oligonucleotide primer

&lt;400&gt; 13

acaattttcac acagca

16

&lt;210&gt; 14

&lt;211&gt; 5668

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 14

gtcacttagg	aaaaggtgtc	ctttcgggca	gccgggctca	gcatgaggaa	cagaaggaat	60
gacactctgg	acagcaccgg	gaccctgtac	tccagcgcgt	ctcggagcac	agacttgtct	120
tacagtga	gagacttggt	gaattttatt	caagcaaatt	ttaagaaacg	agaatgtgtc	180
ttctttacca	aagattccaa	ggccacggag	aatgtgtgca	agtgtggcta	tgcccagagc	240
cagcacatgg	aaggcaccga	gatcaaccaa	agtgagaaat	ggaactacaa	gaaacacacc	300
aaggaatttc	ctaccgacgc	ctttggggat	attcagtttg	agacactggg	gaagaaaggg	360
aagtatatac	gtctgtcctg	cgacacggac	gcggaaatcc	tttacgagct	gctgaccag	420
cactggcacc	tgaaaacacc	caacctgggtc	atttctgtga	ccggggggcgc	caagaacttc	480
gccctgaagc	cgcgcatgcg	caagatcttc	agccgggtca	tctacatcgc	gcagtccaaa	540
ggtgcttgga	ttctcacggg	aggcaccat	tatggcctga	cgaagtacat	cggggaggtg	600
gtgagagata	acaccatcag	caggagtcca	gaggagaata	ttgtggccat	tggcatagca	660
gcttggggca	tgggtctcaa	ccgggacacc	ctcatcagga	attgcgatgc	tgagggtat	720
tttttagccc	agtaccttat	ggatgacttc	acaagggatc	cactgtatat	cctggacaac	780
aaccacacac	atttgcctgt	cgtggacaat	ggctgtcatg	gacatcccac	tgctgaagca	840
aagctccgga	atcagctaga	gaagcatatc	tctgagcgca	ctattcaaga	ttccaactat	900
ggtggcaaga	tccccattgt	gtgttttgcc	caaggaggtg	gaaaagagac	tttgaaagcc	960
atcaatacct	ccatcaaaaa	taaaattcct	tgtgtggtgg	tggaaaggctc	gggccggatc	1020
gctgatgtga	tcgctagcct	ggtggaggtg	gaggatgccc	cgacatcttc	tgccgtcaag	1080
gagaagctgg	tgcgcttttt	accccgccag	gtgtcccggc	tgtctgagga	ggagactgag	1140
agttggatca	aatggctcaa	agaaattctc	gaatgttctc	acctattaac	agttattaaa	1200
atggaagaag	ctggggatga	aattgtgagc	aatgccatct	cctacgctct	atacaaagcc	1260
ttcagcacca	gtgagcaaga	caaggataac	tggaaatgggc	agctgaagct	tctgctggag	1320
tggaaaccagc	tggacttagc	caatgatgag	attttcacca	atgaccgccg	atgggagtct	1380
gctgacccttc	aagaagtcac	gtttacggct	ctcataaagg	acagacccaa	gtttgtccgc	1440
ctctttctgg	agaatggctt	gaacctacgg	aagtttctca	cccatgatgt	cctcactgaa	1500
ctcttctcca	accacttcag	caagcttggtg	taccggaatc	tgcagatcgc	caagaattcc	1560
tataatgatg	cctcctcac	gtttgtctgg	aaactgggtg	cgaacttccg	aagaggcttc	1620
cggaaaggaag	acagaaatgg	ccgggacgag	atggacatag	aactccacga	cgtgtctcct	1680
attactcggc	acccctgca	agctctcttc	atctgggcca	ttcttcagaa	taagaaggaa	1740
ctctccaaag	tcatttgga	gcagaccagg	ggctgcactc	tggcagccct	gggagccagc	1800
aagcttctga	agactctggc	caaagtgaag	aacgacatca	atgctgctgg	ggagtcagag	1860
gagctggcta	atgagtacga	gaccggggct	gttgagctgt	tactgagtg	ttacagcagc	1920

gatgaagact	tggcagaaca	gctgctgggc	tattcctgtg	aagcttgggg	tggaagcaac	1980
tgtctggagc	tggcgggtgga	ggccacagac	cagcatttca	ccgcccagcc	tgggggtccag	2040
aattttcttt	ctaagcaatg	gtatggagag	atttcccag	acaccaagaa	ctggaagatt	2100
atcctgtgtc	tgtttattat	acccttgggt	ggctgtggct	ttgtatcatt	taggaagaaa	2160
cctgtcgaca	agcacaagaa	gctgctttgg	tactatgtgg	cgttcttcac	ctcccccttc	2220
gtggtcttct	cctggaatgt	ggtcttctac	atcgcttcc	tcctgctgtt	tgcctacgtg	2280
ctgctcatgg	atttccattc	ggtgocacac	ccccccgagc	tggctcctgta	ctcgctgggtc	2340
tttgtcctct	tctgtgatga	agtgagacag	tggtagctaa	atgggggtgaa	ttatttttact	2400
gacctgtgga	atgtgatgga	cacgctgggg	cttttttact	tcatagcagg	aattgtattt	2460
cggtccact	cttctaataa	aagctctttg	tattctggac	gagtcatttt	ctgtctggac	2520
tacattattt	tcaacttaag	attgatccac	atttttactg	taagcagaaa	cttaggaccc	2580
aagattataa	tgtcgcagag	gatgctgac	gatgtgttct	tcttctctgtt	cctcttttgcg	2640
gtgtgggtga	tggcctttgg	cgtggccagg	caagggatcc	ttaggcagaa	tgagcagcgc	2700
tggaggtgga	tattccgttc	ggctcatctac	gagccctacc	tggccatggt	cggccagggtg	2760
cccagtgacg	tggatggtac	cacgtatgac	tttgccact	gcaccttcac	tgggaatgag	2820
tccaagccac	tgtgtgtgga	gctggatgag	cacaacctgc	cccggttccc	cgagtggatc	2880
accatcccc	tgtgtgtcat	ctacatgtta	tccaccaaca	tcctgctggt	caacctgctg	2940
gtcgccatgt	ttggctacac	ggtgggcacc	gtccaggaga	acaatgacca	ggtctggaag	3000
ttccagaggt	acttctctgt	gcaggagtac	tgcagccgcc	tcaatatccc	cttcccccttc	3060
atcgtcttcg	cttacttcta	catggtgggt	aagaagtgtc	tcaagtgttg	ctgcaaggag	3120
aaaaacatgg	agtcttctgt	ctgctgtttc	aaaaatgaag	acaatgagac	tctggcatgg	3180
gaggggtgtca	tgaaggaaaa	ctacctgtc	aagatcaaca	caaaagccaa	cgacacctca	3240
gaggaaatga	ggcatcgatt	tagacaactg	gatacaaagc	ttaatgatct	caagggtctt	3300
ctgaaagaga	ttgctaataa	aatcaaataa	aactgtatga	aactctaata	gagaaaaatc	3360
taattatagc	aagatcatat	taaggaatgc	tgatgaacaa	ttttgctatc	gactactaaa	3420
tgagagattt	tcagaccctc	gggtacatgg	tggatgattt	taaatcacc	tagtgtgctg	3480
agaccttgag	aataaagtgt	gtgattgggt	tcatacttga	agacggatat	aaaggaagaa	3540
tatttccttt	atgtgtttct	ccagaatggt	gcctgtttct	ctctgtgtct	caatgcctgg	3600
gactggaggt	tgatagttta	agtgtgttct	taccgcctcc	tttttccttt	aatcttattt	3660
ttgatgaaca	catatatagg	agaacatcta	tcctatgaat	aagaacctgg	tcattgttta	3720
ctcctgtatt	gttattttgt	tcatttccaa	ttgattctct	acttttccct	ttttgtatt	3780
atgtgactaa	ttagtggca	tattgttaaa	agtctctcaa	attaggccag	attctaaaaac	3840
atgctgcagc	aagaggaccc	cgctctcttc	aggaaaagt	ttttcatttc	tcaggatgct	3900
tcttacctgt	cagaggaggt	gacaaggcag	tctcttgctc	tcttggaactc	accaggctcc	3960
tattgaagga	accaccccc	ttcctaaata	tgtgaaaagt	cgcccaaaat	gcaaccttga	4020
aaggcaactac	tgactttgtt	cttattggat	actcctctta	tttattattt	ttccattaaa	4080
aataatagct	ggctattata	gaaaatttag	accatacaga	gatgtagaaa	gaacataaat	4140
tgtccccatt	accttaaggt	aatcactgct	aacaatttct	ggatgggttt	tcaagtctat	4200
tttttttcta	tgtatgtctc	aattctcttt	caaaatttta	cagaatgtta	tcatactaca	4260
tatatacttt	ttatgttaagc	tttttcactt	agtattttat	caaataatgtt	tttattatat	4320
tcatagcctt	cttaaacatt	atatcaataa	ttgcataata	ggcaacctct	agcgattacc	4380
ataattttgc	tcattgaagg	ctatctccag	ttgatcattg	ggatgagcat	ctttgtgcat	4440
gaatcctatt	gctgtatttg	ggaaaatttt	ccaagggttag	attccaataa	atatctattt	4500
attattaaat	attaaaatat	cgatttatta	ttaaaacccat	ttataaggct	ttttcataaa	4560
tgtatagcaa	ataggaatta	ttaacttgag	cataagatat	gagatacatg	aacctgaact	4620
attaaaataa	aatattatat	ttaaccctag	tttaagaaga	agtcaatatg	cttattttaa	4680
tattatggat	ggtgggcaga	tcacttgagg	tcaggagttc	gagaccagcc	tggccaacat	4740
ggcaaaacca	catctctact	aaaaataaaa	aaattagctg	ggtgtgggtg	tgcactcctg	4800
taatccagc	tactcagaag	gctgaggtag	aaagtgtgt	ggaacctggg	aggcggaggt	4860
tgcagtgaac	caagattgca	ccactgcact	ccagccgggg	tgacagagtg	agactccgac	4920
tgaaaataaa	taaaataata	aataaataaa	taaaataata	aatattatgg	atgggtgaagg	4980
gaatgggtata	gaattggaga	gattatctta	ctgaacacct	gtagtcccag	ctttctctgg	5040
aagtgggtggt	atttgagcag	gatgtgcaca	aggcaattga	aatgcccata	attagtttct	5100
cagctttgaa	tacactataa	actcagtggc	tgaaggagga	aatttttagaa	ggaagctact	5160

```

aaaagatcta atttgaaaaa ctacaaaagc attaactaaa aaagtttatt ttccttttgt 5220
ctgggagta gtgaaaataa ctactcacaa cattcactat gtttgcaagg aattaacaca 5280
aataaaagat gccttttttac ttaaagccca agacagaaaaa cttgccaat actgagaagc 5340
aacttgcatt agagagggaa ctgttaaagtg ttttcaaccc agttcatctg gtggatgttt 5400
ttgcaggtta ctctgagaat tttgcttatg aaaaatcatt attttttagtg tagttcacaa 5460
taatgtattg aacatacttc taatcaaagg tgctatgtcc ttgtgtatgg tactaaatgt 5520
gtcctgtgta cttttgcaca actgagaatc ctgcgggcttg gtttaagtga tgtgttcacg 5580
aaataaataa tggaggaatt gtcaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa 5640
aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa

```

&lt;210&gt; 15

&lt;211&gt; 1095

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 15

Met Arg Asn Arg Arg Asn Asp Thr Leu Asp Ser Thr Arg Thr Leu Tyr

1 5 10 15

Ser Ser Ala Ser Arg Ser Thr Asp Leu Ser Tyr Ser Glu Ser Asp Leu

20 25 30

Val Asn Phe Ile Gln Ala Asn Phe Lys Lys Arg Glu Cys Val Phe Phe

35 40 45

Thr Lys Asp Ser Lys Ala Thr Glu Asn Val Cys Lys Cys Gly Tyr Ala

50 55 60

Gln Ser Gln His Met Glu Gly Thr Gln Ile Asn Gln Ser Glu Lys Trp

65 70 75 80

Asn Tyr Lys Lys His Thr Lys Glu Phe Pro Thr Asp Ala Phe Gly Asp

85 90 95

Ile Gln Phe Glu Thr Leu Gly Lys Lys Gly Lys Tyr Ile Arg Leu Ser

100 105 110

Cys Asp Thr Asp Ala Glu Ile Leu Tyr Glu Leu Leu Thr Gln His Trp  
115 120 125  
His Leu Lys Thr Pro Asn Leu Val Ile Ser Val Thr Gly Gly Ala Lys  
130 135 140  
Asn Phe Ala Leu Lys Pro Arg Met Arg Lys Ile Phe Ser Arg Leu Ile  
145 150 155 160  
Tyr Ile Ala Gln Ser Lys Gly Ala Trp Ile Leu Thr Gly Gly Thr His  
165 170 175  
Tyr Gly Leu Thr Lys Tyr Ile Gly Glu Val Val Arg Asp Asn Thr Ile  
180 185 190  
Ser Arg Ser Ser Glu Glu Asn Ile Val Ala Ile Gly Ile Ala Ala Trp  
195 200 205  
Gly Met Val Ser Asn Arg Asp Thr Leu Ile Arg Asn Cys Asp Ala Glu  
210 215 220  
Gly Tyr Phe Leu Ala Gln Tyr Leu Met Asp Asp Phe Thr Arg Asp Pro  
225 230 235 240  
Leu Tyr Ile Leu Asp Asn Asn His Thr His Leu Leu Leu Val Asp Asn  
245 250 255  
Gly Cys His Gly His Pro Thr Val Glu Ala Lys Leu Arg Asn Gln Leu  
260 265 270  
Glu Lys His Ile Ser Glu Arg Thr Ile Gln Asp Ser Asn Tyr Gly Gly  
275 280 285  
Lys Ile Pro Ile Val Cys Phe Ala Gln Gly Gly Gly Lys Glu Thr Leu  
290 295 300  
Lys Ala Ile Asn Thr Ser Ile Lys Asn Lys Ile Pro Cys Val Val Val  
305 310 315 320  
Glu Gly Ser Gly Arg Ile Ala Asp Val Ile Ala Ser Leu Val Glu Val

325 330 335  
Glu Asp Ala Pro Thr Ser Ser Ala Val Lys Glu Lys Leu Val Arg Phe  
340 345 350  
Leu Pro Arg Thr Val Ser Arg Leu Ser Glu Glu Glu Thr Glu Ser Trp  
355 360 365  
Ile Lys Trp Leu Lys Glu Ile Leu Glu Cys Ser His Leu Leu Thr Val  
370 375 380  
Ile Lys Met Glu Glu Ala Gly Asp Glu Ile Val Ser Asn Ala Ile Ser  
385 390 395 400  
Tyr Ala Leu Tyr Lys Ala Phe Ser Thr Ser Glu Gln Asp Lys Asp Asn  
405 410 415  
~~Trp Asn Gly Gln Leu Lys Leu Leu Leu Glu Trp Asn Gln Leu Asp Leu~~  
420 425 430  
Ala Asn Asp Glu Ile Phe Thr Asn Asp Arg Arg Trp Glu Ser Ala Asp  
435 440 445  
Leu Gln Glu Val Met Phe Thr Ala Leu Ile Lys Asp Arg Pro Lys Phe  
450 455 460  
Val Arg Leu Phe Leu Glu Asn Gly Leu Asn Leu Arg Lys Phe Leu Thr  
465 470 475 480  
His Asp Val Leu Thr Glu Leu Phe Ser Asn His Phe Ser Thr Leu Val  
485 490 495  
Tyr Arg Asn Leu Gln Ile Ala Lys Asn Ser Tyr Asn Asp Ala Leu Leu  
500 505 510  
Thr Phe Val Trp Lys Leu Val Ala Asn Phe Arg Arg Gly Phe Arg Lys  
515 520 525  
Glu Asp Arg Asn Gly Arg Asp Glu Met Asp Ile Glu Leu His Asp Val  
530 535 540

Ser Pro Ile Thr Arg His Pro Leu Gln Ala Leu Phe Ile Trp Ala Ile  
545 550 555 560  
Leu Gln Asn Lys Lys Glu Leu Ser Lys Val Ile Trp Glu Gln Thr Arg  
565 570 575  
Gly Cys Thr Leu Ala Ala Leu Gly Ala Ser Lys Leu Leu Lys Thr Leu  
580 585 590  
Ala Lys Val Lys Asn Asp Ile Asn Ala Ala Gly Glu Ser Glu Glu Leu  
595 600 605  
Ala Asn Glu Tyr Glu Thr Arg Ala Val Glu Leu Phe Thr Glu Cys Tyr  
610 615 620  
Ser Ser Asp Glu Asp Leu Ala Glu Gln Leu Leu Val Tyr Ser Cys Glu  
625 630 635 640  
Ala Trp Gly Gly Ser Asn Cys Leu Glu Leu Ala Val Glu Ala Thr Asp  
645 650 655  
Gln His Phe Thr Ala Gln Pro Gly Val Gln Asn Phe Leu Ser Lys Gln  
660 665 670  
Trp Tyr Gly Glu Ile Ser Arg Asp Thr Lys Asn Trp Lys Ile Ile Leu  
675 680 685  
Cys Leu Phe Ile Ile Pro Leu Val Gly Cys Gly Phe Val Ser Phe Arg  
690 695 700  
Lys Lys Pro Val Asp Lys His Lys Lys Leu Leu Trp Tyr Tyr Val Ala  
705 710 715 720  
Phe Phe Thr Ser Pro Phe Val Val Phe Ser Trp Asn Val Val Phe Tyr  
725 730 735  
Ile Ala Phe Leu Leu Leu Phe Ala Tyr Val Leu Leu Met Asp Phe His  
740 745 750  
Ser Val Pro His Pro Pro Glu Leu Val Leu Tyr Ser Leu Val Phe Val

755	760	765
Leu Phe Cys Asp Glu Val Arg Gln Trp Tyr Val Asn Gly Val Asn Tyr		
770	775	780
Phe Thr Asp Leu Trp Asn Val Met Asp Thr Leu Gly Leu Phe Tyr Phe		
785	790	795
Ile Ala Gly Ile Val Phe Arg Leu His Ser Ser Asn Lys Ser Ser Leu		
805	810	815
Tyr Ser Gly Arg Val Ile Phe Cys Leu Asp Tyr Ile Ile Phe Thr Leu		
820	825	830
Arg Leu Ile His Ile Phe Thr Val Ser Arg Asn Leu Gly Pro Lys Ile		
835	840	845
<del>Ile Met Leu Gln Arg Met Leu Ile Asp Val Phe Phe Phe Leu Phe Leu</del>		
850	855	860
Phe Ala Val Trp Met Val Ala Phe Gly Val Ala Arg Gln Gly Ile Leu		
865	870	875
Arg Gln Asn Glu Gln Arg Trp Arg Trp Ile Phe Arg Ser Val Ile Tyr		
885	890	895
Glu Pro Tyr Leu Ala Met Phe Gly Gln Val Pro Ser Asp Val Asp Gly		
900	905	910
Thr Thr Tyr Asp Phe Ala His Cys Thr Phe Thr Gly Asn Glu Ser Lys		
915	920	925
Pro Leu Cys Val Glu Leu Asp Glu His Asn Leu Pro Arg Phe Pro Glu		
930	935	940
Trp Ile Thr Ile Pro Leu Val Cys Ile Tyr Met Leu Ser Thr Asn Ile		
945	950	955
Leu Leu Val Asn Leu Leu Val Ala Met Phe Gly Tyr Thr Val Gly Thr		
965	970	975

Val Gln Glu Asn Asn Asp Gln Val Trp Lys Phe Gln Arg Tyr Phe Leu  
980 985 990

Val Gln Glu Tyr Cys Ser Arg Leu Asn Ile Pro Phe Pro Phe Ile Val  
995 1000 1005

Phe Ala Tyr Phe Tyr Met Val Val Lys Lys Cys Phe Lys Cys Cys Cys  
1010 1015 1020

Lys Glu Lys Asn Met Glu Ser Ser Val Cys Cys Phe Lys Asn Glu Asp  
1025 1030 1035 104

Asn Glu Thr Leu Ala Trp Glu Gly Val Met Lys Glu Asn Tyr Leu Val  
1045 1050 1055

Lys Ile Asn Thr Lys Ala Asn Asp Thr Ser Glu Glu Met Arg His Arg  
1060 1065 1070

Phe Arg Gln Leu Asp Thr Lys Leu Asn Asp Leu Lys Gly Leu Leu Lys  
1075 1080 1085

Glu Ile Ala Asn Lys Ile Lys  
1090 1095

<210> 16

<211> 22

<212> DNA

<213> Artificial Sequence

<220>

<221> primer\_bind

<222> (1)...(22)

<223> NP1 primer



---

<400> 16

tcgagcggcc gcccgggcag gt

22

<210> 17

<211> 22

<212> DNA

<213> Artificial Sequence

<220>

<221> primer\_bind

<222> (1)...(22)

<223> NP2 primer

---

<400> 17

agggcgtggt gcggagggcg gt

22

<210> 18

<211> 16

<212> DNA

<213> Artificial Sequence

<220>

<221> primer\_bind

<222> (1)...(16)

<223> M13 reverse primer

<400> 18

caggaaacag ctatga

16

<210> 19

<211> 18

<212> DNA

<213> Artificial Sequence

<220>

<221> primer\_bind

<222> (1)...(18)

<223> M13 forward primer

<400> 19

gtaaaacgac ggccagtg

18

<210> 20

<211> 27

<212> DNA

<213> Artificial Sequence

<220>

<221> primer\_bind

<222> (1)...(27)

<223> AP1 primer

<400> 20

ccatcctaatac gactcact atagggc

27

<210> 21

<211> 26

<212> DNA

<213> Artificial Sequence

<220>

<221> primer\_bind

<222> (1)...(26)

<223> A79331 primer

<400> 21

gccgagtaat aggagacacg tcgtgg

26

<210> 22

<211> 23

<212> DNA

<213> Artificial Sequence

<220>

<221> primer\_bind

<222> (1)...(23)

<223> A79326 primer

<400> 22

tggaactgg ttgcgaactt ccg

23

<210> 23

<211> 23

<212> DNA

<213> Artificial Sequence

<220>

<221> primer\_bind

<222> (1)...(23)

<223> AP2 primer

<400> 23

actcactata gggctcgagc ggc

23

<210> 24

<211> 25

<212> DNA

<213> Artificial Sequence

<220>

<221> primer\_bind

<222> (1)...(25)

<223> A79328 primer

<400> 24

caaagtcatt tggcagcaga ccagg

25

<210> 25

---

<211> 21

<212> DNA

<213> Artificial Sequence

<220>

<221> primer\_bind

<222> (1) ... (21)

<223> A80552 primer

<400> 25

gatttttcacc aatgaccgcc g

21

---

<210> 26

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<221> primer\_bind

<222> (1) ... (20)

<223> A80553 primer

<400> 26

ccccagcagc attgatgtcg

20

---

<210> 27

<211> 1690

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 27

```

gtcacttagg aaaaggtgtc ctttcgggca gccgggctca gcatgaggaa cagaaggaat      60
gacactctgg acagcaccgc gaccctgtac tccagcgcgt ctcgagcac agacttgtct      120
tacagtgaag ggcacttggg gaattttatt caagcaaatt ttaagaaacg agaatgtgtc      180
ttctttacca aagattccaa ggccacggag aatgtgtgca agtgtggcta tgcccagagc      240
cagcacatgg aaggcaccca gatcaaccaa agtgagaaat ggaactacaa gaaacacacc      300
aaggaatttc ctaccgacgc ctttggggat attcagtttg agacactggg gaagaaaggg      360
aagtatatac gtctgtcctg cgacacggac gcggaaatcc ttacgagct gctgaccag      420
cactggcacc tgaaaacacc caacctgggc atttctgtga ccgggggcgc caagaacttc      480
gccctgaagc cgcgcacgcg caagatcttc agccggctca tctacatcgc gcagtccaaa      540
ggtgcttggg ttctcacggg aggcacccat tatggcctga cgaagtacat cggggagggtg      600
gtgagagata acaccatcag caggagttca gaggagaata ttgtggccat tggcatagca      660
gcttggggca tgggtctcaa ccgggacacc ctcatcagga attgcgatgc tgagggtat      720
tttttagccc agtaccttat ggatgacttc acaagggatc cactgtatat cctggacaac      780
aaccacacac atttgctgct cgtggacaat ggctgtcatg gacatcccac tgtcgaagca      840
aagctccgga atcagctaga gaagcatatc tctgagcgca ctattcaaga ttccaactat      900
ggtggcaaga tccccattgt gtgttttgcc caaggagggtg gaaaagagac tttgaaagcc      960
atcaatacct ccatcaaaaa taaaattcct tgtgtggtgg tggaaggctc gggccggatc     1020
gctgatgtga tcgctagcct ggtggagggtg gaggatgccc cgacatcttc tgccgtcaag     1080
gagaagctgg tgcgcttttt accccgcacg gtgtcccggc tgtctgagga ggagactgag     1140
agttggatca aatggctcaa agaaattctc gaatgttctc acctattaac agttattaaa     1200
atggaagaag ctggggatga aattgtgagc aatgccatct cctacgctct atacaaagcc     1260
ttcagcacca gtgagcaaga caaggataac tggaatgggc agctgaagct tctgctggag     1320
tggaaccagc tggacttagc caatgatgag attttcacca atgaccgccg atgggagtct     1380

```

---

gctgaccttc aagaagtcac gtttacggct ctcataaagg acagacccaa gtttgctccgc	1440
ctctttcttg agaatggctt gaacctacgg aagtttctca cccatgatgt cctcactgaa	1500
ctctttctca accacttcag cacgcttggtg taccggaatc tgcagatcgc caagaattcc	1560
tataatgatg cctcctcac gtttgctctgg aaactgggtg cgaacttccg aagaggcttc	1620
cggaaggaag acagaaatgg ccgggacgag atggacatag aactccacga cgtgtctcct	1680
attactcggc	1690

&lt;210&gt; 28

&lt;211&gt; 3848

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 28

---

caaagtgaag aacgacatca atgctgctgg ggagtccgag gagctggcta atgagtacga	60
gacccgggct gttgagctgt tcaactgagt ttacagcagc gatgaagact tggcagaaca	120
gctgctggtc tattcctgtg aagcttgggg tggaagcaac tgtctggagc tggcgggtgga	180
ggccacagac cagcatttca ccgcccagcc tggggctccag aattttcttt ctaagcaatg	240
gtatggagag atttcccag acaccaagaa ctggaagatt atcctgtgtc tgtttattat	300
acccttgggt ggctgtggct ttgtatcatt taggaagaaa cctgtcgaca agcacaagaa	360
gctgcttttg tactatgtgg cgttcttcac ctcccccttc gtggctcttct cctggaatgt	420
ggctcttctac atcgcttcc tctgctgtt tgcctacgtg ctgctcatgg atttccattc	480
gggtgccacac cccccgagc tggctcctgta ctgctgggc tttgtcctct tctgtgatga	540
agtgagacag tggtagtaa atggggtgaa ttattttact gacctgtgga atgtgatgga	600
cacgctgggg cttttttact tcatagcagg aattgtattt cggctccact cttctaataa	660
aagctctttg tattctggac gagtcatttt ctgtctggac tacattattt tcaactaag	720
attgatccac atttttactg taagcagaaa ctaggaccc aagattataa tgctgcagag	780
gatgctgac gatgtgttct tcttctgtt cctctttgcg gtgtggatgg tggcctttgg	840

cgtggccagg caagggatcc ttaggcagaa tgagcagcgc tggaggtgga tattccgttc 900  
 ggtcatctac gagccctacc tggccatgtt cggccagggtg cccagtgcg tggatggtac 960  
 cacgtatgac tttgcccact gcaccttcac tgggaatgag tccaagccac tgtgtgtgga 1020  
 gctggatgag cacaacctgc cccggttccc cgagtggatc accatcccc tgggtgtgcat 1080  
 ctacatgtta tccaccaaca tctgtctggt caacctgctg gtcgccatgt ttggctacac 1140  
 ggtgggcacc gtccaggaga acaatgacca ggtctggaag ttccagaggt acttcctggt 1200  
 gcaggagtac tgcagccgcc tcaatatccc cttccccttc atcgtcttcg cttacttcta 1260  
 catggtggtg aagaagtgtc tcaagtgttg ctgcaaggag aaaaacatgg agtcttctgt 1320  
 ctgctgtttc aaaaatgaag acaatgagac tctggcatgg gaggggtgtca tgaaggaaaa 1380  
 ctaccttgtc aagatcaaca caaaagccaa cgacacctca gaggaatga ggcacgatt 1440  
 tagacaactg gatacaaagc ttaatgatct caagggctct ctgaaagaga ttgctaataa 1500  
 aatcaaataa aactgtatga aactctaata gagaaaaatc taattatagc aagatcatat 1560  
 taaggaatgc tgatgaacaa ttttgcatac gactactaaa tgagagattt tcagaccctt 1620  
 gggtagcatgg tggatgattt taaatcacc tagtgtgctg agacctgag aataaagtgt 1680  
 gtgattgggt tcatacttga agacggatat aaaggaagaa tatttccttt atgtgtttct 1740  
 ccagaatggt gcctgtttct ctctgtgtct caatgcctgg gactggaggt tgatagttaa 1800  
 agtgtgttct taccgcctcc tttttccttt aatcttattt ttgatgaaca catatatagg 1860  
 agaacatcta tcctatgaat aagaacctgg tcatgcttta ctctgtatt gttattttgt 1920  
 tcatttccaa ttgattctct acttttcctt tttttgtatt atgtgactaa ttagttggca 1980  
 tattgttaaa agtctctcaa attaggccag attctaaaac atgctgcagc aagaggacct 2040  
 cgctctcttc aggaaaagtg ttttcatttc tcaggatgct tcttacctgt cagaggaggt 2100  
 gacaaggcag tctcttgcct tcttggaact accaggctcc tattgaagga accaccccca 2160  
 ttctaaataa tgtgaaaagt cgcccaaat gcaaccttga aaggcactac tgactttggt 2220  
 cttattggat actcctctta tttattattt ttccattaaa aataatagct ggctattata 2280  
 gaaaatttag accatacaga gatgtagaaa gaacataaat tgtcccatc accttaaggt 2340  
 aatcaactgt aacaatttct ggatgggttt tcaagtctat ttttttcta tgtatgtctc 2400  
 aattctcttt caaaatttta cagaatgtta tcatactaca tatatacttt ttatgtaagc 2460



tttttcactt agtattttat caaatatggt tttattatat tcatagcctt cttaaacatt	2520
atatcaataa ttgcataata ggcaacctct agcgattacc ataattttgc tcattgaagg	2580
ctatctccag ttgatcattg ggatgagcat ctttgtgcat gaatcctatt gctgtatttg	2640
ggaaaatttt ccaagggttag attccaataa atatctattt attattaaat attaaaatat	2700
cgatttatta ttaaaacctat ttataaggct ttttcataaa tgtatagcaa ataggaatta	2760
ttaacttgag cataagatat gagatacatg aacctgaact attaaaataa aatattatat	2820
ttaaccctag tttaagaaga agtcaatatg cttattttaa tattatggat ggtgggcaga	2880
tcacttgagg tcaggagttc gagaccagcc tggccaacat ggcaaaacca catctctact	2940
aaaaataaaa aaattagctg ggtgtggtgg tgcactcctg taatcccagc tactcagaag	3000
gctgaggtac aagaattgct ggaacctggg aggcggaggt tgcagtgaac caagattgca	3060
ccactgcact ccagccgggg tgacagagtg agactccgac tgaaaataaa taaataaata	3120
aataaataaa taaataaata aatattatgg atggtgaagg gaatggtata gaattggaga	3180
gattatctta ctgaacacct gtagtcccag ctttctctgg aagtgggtgg atttgagcag	3240
gatgtgcaca aggcaattga aatgcccata attagtttct cagctttgaa tacactataa	3300
actcagtggc tgaaggagga aatttttagaa ggaagctact aaaagatcta atttgaaaaa	3360
ctacaaaagc attaaactaaa aaagtttatt ttccttttgt ctgggcagta gtgaaaataa	3420
ctactcacia cattcactat gtttgcaagg aattaacaca aataaaagat gcctttttac	3480
ttaaacgcca agacagaaaa cttgcccatt actgagaagc aacttgcat agagagggaa	3540
ctgttaaattg ttttcaaccc agttcatctg gtggatgttt ttgcaggtta ctctgagaat	3600
tttgcttatg aaaaatcatt attttttagtg tagttcacia taatgtattg aacatacttc	3660
taatcaaagg tgctatgtcc ttgtgtatgg tactaaatgt gtctgtgta cttttgcaca	3720
actgagaatc ctgcggcttg gtttaattgag tgtgttcatg aaataaataa tggaggaatt	3780
gtcaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa	3840
aaaaaaaaa	3848

&lt;210&gt; 29

&lt;211&gt; 342

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 29

cggaatctgc agatcgccaa gaattcctat aatgatgccc tcctcacgtt tgtctggaaa	60
ctgggttgca acttccgaag aggcttccgg aaggaagaca gaaatggccg ggacgagatg	120
gacatagaac tccacgacgt gtctcctatt actcggcacc ccctgcaagc tctcttcac	180
tgggccattc ttcagaataa gaaggaactc tccaaagtca tttgggagca gaccaggggc	240
tgcactctgg cagccctggg agccagcaag cttctgaaga ctctggccaa agtgaagaac	300
gacatcaatg ctgctgggga gtccgaggag ctggctaag ag	342

## INDICATIONS RELATING TO A DEPOSITED MICROORGANISM

(PCT Rule 13bis)

A. The indications made below relate to the microorganism referred to in the description on page <u>2</u> , line <u>10-15</u>	
B. IDENTIFICATION OF DEPOSIT <span style="float: right;">Further deposits are identified on an additional sheet <input type="checkbox"/></span>	
Name of depositary institution American Type Culture Collection (ATCC)	
Address of depositary institution (including postal code and country) 10801 University Blvd. Manassas, VA 20110-1109	
Date of deposit 06 August 1998 (06.08.98)	Accession Number ATCC 98829
C. ADDITIONAL INDICATIONS (leave blank if not applicable) <span style="float: right;">This information is continued on an additional sheet <input type="checkbox"/></span>	
<p>The relevant invention includes the nucleotide sequence (SEQ ID NO:14) and the polypeptide sequence (SEQ ID NO:15) of a prostate tumor antigen SP1-4. The cDNA inserts of three pCR2.1 plasmid vectors together make up the full-length SP 1-4 (SEQ ID NO:14) coding sequence and they are represented by the referenced ATCC deposits. ATCC 98829 is the reference number for deposit of a plasmid designated "pCR2.1/SP 1-4/3' RACE" which contains the DNA sequence represented by SEQ ID NO:28 and corresponds to nucleotides 1821 to 5668 of the full-length SP 1-4 (SEQ ID NO:14) coding sequence.</p> <p>The vector represented by the above-referenced ATCC deposit was prepared from the commercially available pCR2.1 plasmid vector, purchased from Invitrogen, San Diego, CA.</p>	
D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE (if the indications are not for all designated States)	
E. SEPARATE FURNISHING OF INDICATIONS (leave blank if not applicable)	
The indications listed below will be submitted to the International Bureau later (specify the general nature of the indications e.g., "Accession Number of Deposit")	

For receiving Office use only



This sheet was received with the international application

Authorized officer

For International Bureau use only



This sheet was received by the International Bureau on:

06 OCT 1998

Authorized officer

N. W. 546  
NICOLA WOLFF

Applicant's or agent's file  
reference number

36-0015-41

International application  
PCT/US98/1

58

## INDICATIONS RELATING TO A DEPOSITED MICROORGANISM

(PCT Rule 13bis)

<b>A.</b> The indications made below relate to the microorganism referred to in the description on page <u>2</u> , line <u>10-15</u>	
<b>B. IDENTIFICATION OF DEPOSIT</b> Further deposits are identified on an additional sheet <input type="checkbox"/>	
Name of depositary institution American Type Culture Collection (ATCC)	
Address of depositary institution (including postal code and country) 10801 University Blvd. Manassas, VA 20110-1109	
Date of deposit 06 August 1998 (06.08.98)	Accession Number ATCC 98828
<b>C. ADDITIONAL INDICATIONS</b> (leave blank if not applicable) This information is continued on an additional sheet <input type="checkbox"/>	
<p>The relevant invention includes the nucleotide sequence (SEQ ID NO:14) and the polypeptide sequence (SEQ ID NO:15) of a prostate tumor antigen SP1-4. The cDNA inserts of three pCR2.1 plasmid vectors together make up the full-length SP 1-4 (SEQ ID NO:14) coding sequence and they are represented by the referenced ATCC deposits.</p> <p>ATCC 98828 is the reference number for deposit of a plasmid designated "pCR2.1/SP 1-4/5' RACE" which contains the DNA sequence represented by SEQ ID NO:27 and corresponds to nucleotides 1 to 1690 of the full-length SP 1-4 (SEQ ID NO:14) coding sequence.</p> <p>The vector represented by the above-referenced ATCC deposit was prepared from the commercially available pCR2.1 plasmid vector, purchased from Invitrogen, San Diego, CA.</p>	
<b>D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE</b> (if the indications are not for all designated States)	
<b>E. SEPARATE FURNISHING OF INDICATIONS</b> (leave blank if not applicable)	
The indications listed below will be submitted to the International Bureau later (specify the general nature of the indications e.g., "Accession Number of Deposit")	

For receiving Office use only



This sheet was received with the international application

Authorized officer

For International Bureau use only



This sheet was received by the International Bureau on:

06 OCT 1998

Authorized officer

N. WOLFE  
NICOLA WOLFE

Applicant's or agent's file  
reference number

7536-15.41

International application No

PCT/US 7058

## INDICATIONS RELATING TO A DEPOSITED MICROORGANISM

(PCT Rule 13bis)

<b>A.</b> The indications made below relate to the microorganism referred to in the description on page <u>2</u> , line <u>10-15</u>	
<b>B. IDENTIFICATION OF DEPOSIT</b> Further deposits are identified on an additional sheet <input type="checkbox"/>	
Name of depositary institution American Type Culture Collection (ATCC)	
Address of depositary institution (including postal code and country) 10801 University Blvd. Manassas, VA 20110-1109	
Date of deposit 06 August 1998 (06.08.98)	Accession Number ATCC 98827
<b>C. ADDITIONAL INDICATIONS</b> (leave blank if not applicable) This information is continued on an additional sheet <input type="checkbox"/>	
<p>The relevant invention includes the nucleotide sequence (SEQ ID NO:14) and the polypeptide sequence (SEQ ID NO:15) of a prostate tumor antigen SP1-4. The cDNA inserts of three pCR2.1 plasmid vectors together make up the full-length SP 1-4 (SEQ ID NO:14) coding sequence and they are represented by the referenced ATCC deposits.</p> <p>ATCC 98827 is the reference number for deposit of a plasmid designated "pCR2.1/SP 1-4" which contains the DNA sequence represented by SEQ ID NO:29 and corresponds to nucleotides 1534 to 1875 of the full-length SP 1-4 (SEQ ID NO:14) coding sequence.</p> <p>The vector represented by the above-referenced ATCC deposit was prepared from the commercially available pCR2.1 plasmid vector, purchased from Invitrogen, San Diego, CA.</p>	
<b>D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE</b> (if the indications are not for all designated States)	
<b>E. SEPARATE FURNISHING OF INDICATIONS</b> (leave blank if not applicable)	
The indications listed below will be submitted to the International Bureau later (specify the general nature of the indications e.g., "Accession Number of Deposit")	

For receiving Office use only



This sheet was received with the international application

Authorized officer

For International Bureau use only



This sheet was received by the International Bureau on:

06 OCT 1998

Authorized officer

NWOLFF  
NICOLA WOLFF





## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>6</sup> :</b> <b>C12N 15/12, C07K 14/705, C12N 5/10, C12Q 1/68, C12N 15/62, C07K 16/28</b>	<b>A3</b>	<b>(11) International Publication Number:</b> <b>WO 99/09166</b> <b>(43) International Publication Date:</b> 25 February 1999 (25.02.99)
<b>(21) International Application Number:</b> PCT/US98/17058 <b>(22) International Filing Date:</b> 18 August 1998 (18.08.98)  <b>(30) Priority Data:</b> 60/056,110 20 August 1997 (20.08.97) US 09/112,096 9 July 1998 (09.07.98) US  <b>(71) Applicant (for all designated States except US):</b> DENDREON CORPORATION [US/US]; 291 North Bernardo Avenue, Mountain View, CA 94043 (US).  <b>(72) Inventors; and</b> <b>(75) Inventors/Applicants (for US only):</b> LAUS, Reiner [DE/US]; 3813 Porto Rosa Way, San Carlos, CA 94070 (US). SHAPERO, Michael, H. [US/US]; 2449 Carson Street, Redwood City, CA 94061 (US). TSAVALER, Larisa [US/US]; 43 Walnut Avenue, Atherton, CA 94027 (US).	<b>(81) Designated States:</b> AU, CA, JP, NZ, US, European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).  <b>Published</b> <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>  <b>(88) Date of publication of the international search report:</b> 3 June 1999 (03.06.99)	
<b>(74) Agents:</b> JUDGE, Linda, R. et al.; Dehlinger & Associates, P.O. Box 60850, Palo Alto, CA 94306-0850 (US).		
<b>(54) Title:</b> PROSTATE TUMOR POLYNUCLEOTIDE AND ANTIGEN COMPOSITIONS  <b>(57) Abstract</b>  The present invention is directed to novel polynucleotides and the polypeptides encoded by them, each of which are specific to human prostate tumor cells. The present invention further provides chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, and antibodies which bind to the polypeptides of the present invention. Also provided herein are methods for producing the polypeptides of the present invention, as are detection assays that detect the presence of tumor cells in tissue or bodily fluid samples and methods for identifying novel compositions which modulate the activity of prostate tumor antigens and the use of such compositions in diagnosis and treatment of disease.		

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon			PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakhstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		



# INTERNATIONAL SEARCH REPORT

Ir [REDACTED] Application No.  
PC [REDACTED] 98/17058

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 C12N15/12 C07K14/705 C12N5/10 C12Q1/68 C12N15/62  
C07K16/28

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C07K C12N C12Q

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	HILLIER L ET AL: "Homo sapiens cDNA clone 788034 (AC AA452310)" EMEST8 DATABASE, EMBL HEIDELBERG, GERMANY, 11 June 1997, XP002085388 see nucleotides 450-598 see abstract ---	7-9,19
X	WO 96 30389 A (MILLENIUM PHARM INC) 3 October 1996 see amino acids 202-211, 267-277, and 959-968 of SEQ ID NO: 9 (pp. 151-156) see abstract; claims 9,11-24; figure 6; example 1 see page 16 - page 125 --- -/--	12,13,18

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

\* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

31 March 1999

Date of mailing of the international search report

15.04.99

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Oderwald, H

# INTERNATIONAL SEARCH REPORT

ational Application No

PCT/US 98/17058

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	NCI-CGAP: "Homo sapiens cDNA clone IMAGE:940638 (accession number AA493512)" EMEST DATABASE, EMBL HEIDELBERG, GERMANY, 28 June 1997, XP002098494 see nucleotides 46-285 see abstract -----	4,5,7-9, 19
X	ARMBRUSTER D A: "PROSTATE-SPECIFIC ANTIGEN: BIOCHEMISTRY, ANALYTICAL METHODS, AND CLINICAL APPLICATION" CLINICAL CHEMISTRY, vol. 39, no. 2, 1993, pages 181-195, XP000605382 see the whole document -----	18
A	WO 94 09820 A (SLOAN KETTERING INST CANCER ;ISRAELI RON S (US); HESTON WARREN D W) 11 May 1994 see the whole document -----	
A	WO 95 30758 A (MAYO FOUNDATION ;HYBRITECH INC (US); TINDALL DONALD J (US); YOUNG) 16 November 1995 see the whole document -----	
A	BLOK L J ET AL: "ISOLATION OF CDNAS THAT ARE DIFFERENTIALLY EXPRESSED BETWEEN ANDROGEN-DEPENDENT AND ANDROGEN-INDEPENDENT PROSTATE CARCINOMA CELLS USING DIFFERENTIAL DISPLAY PCR" PROSTATE, vol. 26, no. 4, April 1995, pages 213-224, XP000611577 -----	

# INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US 98/17058

## Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:
  
2. ☐ Claims Nos.:  
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
  
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

see additional sheet

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
  
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
  
3. ☒ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:  
  
(1-3,7-10,13,16-19 all partially), (4-6,12,15 all complete) (inventions 1 and 9)
  
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

### Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☒ No protest accompanied the payment of additional search fees.

# INTERNATIONAL SEARCH REPORT

International Application No. PCT/US 98/17058

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

1. Claims: 1-3,7-10,18,19 all partially

A polynucleotide comprising SEQ ID NO:1, a vector comprising said polynucleotide, a host transformed with said vector, a process for producing a polypeptide encoded by said polynucleotide, a method for detecting the expression of said antigen, a method of detecting tumor cells by PCR involving said polynucleotide.

2. Claims: 1-3, 7-10, 18, 19 all partially

same as in invention 1 but comprising SEQ ID NO: 2.

3. Claims: 1-3, 7-10, 18, 19 all partially

same as in invention 1 but comprising SEQ ID NO: 3.

4. Claims: 1-3, 7-10, 18, 19 all partially

same as in invention 1 but comprising SEQ ID NO: 4.

5. Claims: 1-3, 7-10, 13, 16-19 all partially, 11, 14

A polynucleotide comprising SEQ ID NO:5, a vector comprising said polynucleotide, a host transformed with said vector, a process for producing a polypeptide encoded by said polynucleotide, a peptide consisting of SEQ ID NO: 9, 10 or 11, a fusion protein comprising said peptide, an antibody binding to said peptide, a method for detecting the expression of said polynucleotide, a method of detecting tumor cells by PCR involving said polynucleotide.

6. Claims: 1-3, 7-10, 18, 19 all partially

same as in invention 1 but comprising SEQ ID NO: 6.

7. Claims: 1-3, 7-10, 18, 19 all partially

same as in invention 1 but comprising SEQ ID NO: 7.

8. Claims: 1-3, 7-10, 18, 19 all partially

same as in invention 1 but comprising SEQ ID NO: 8.

# INTERNATIONAL SEARCH REPORT

International Application No. PCT/US 98/17058

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

9. Claims: 1-3, 7-10, 13, 16-19 all partially, 4-6, 12, 15

A polynucleotide comprising SEQ ID NO:14, a vector comprising said polynucleotide, a host transformed with said vector, a process for producing a polypeptide encoded by said polynucleotide, a peptide consisting of SEQ ID NO: 15, a fusion protein comprising said peptide, an antibody binding to said peptide, a method for detecting the expression of said polynucleotide, a method of detecting tumor cells by PCR involving said polynucleotide.

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No.

PCT/US 98/17058

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9630389 A	03-10-1996	US 5633161 A	27-05-1997
		AU 5437896 A	16-10-1996
		CA 2216717 A	03-10-1996
		EP 0817792 A	14-01-1998
		US 5674739 A	07-10-1997
WO 9409820 A	11-05-1994	CA 2147499 A	11-05-1994
		EP 0668777 A	30-08-1995
		JP 8506005 T	02-07-1996
		US 5538866 A	23-07-1996
WO 9530758 A	16-11-1995	AU 699748 B	10-12-1998
		AU 2639095 A	29-11-1995
		CA 2189774 A	16-11-1995
		EP 0804593 A	05-11-1997
		JP 10500294 T	13-01-1998
		ZA 9503727 A	07-08-1996
		AU 5788996 A	21-11-1996
		CA 2219876 A	07-11-1996
		EP 0826056 A	04-03-1998
		WO 9634964 A	07-11-1996